Delaware |
7374 |
88-0950636 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification No.) |
Large accelerated filer |
☐ |
Accelerated filer |
☐ | |||
|
|
|
|
|
|
|
☒ |
Smaller reporting company |
|||||
|
|
|
|
|
|
|
Emerging growth company |
Page |
||||
8 | ||||
16 | ||||
54 | ||||
56 | ||||
57 | ||||
76 | ||||
97 | ||||
104 | ||||
128 | ||||
131 | ||||
133 | ||||
139 | ||||
152 | ||||
158 | ||||
161 | ||||
161 | ||||
161 | ||||
162 | ||||
F-1 |
• | our ability to achieve milestones, technological advancements, including with respect to executing on our technology roadmap and developing practical applications; |
• | the potential of quantum computing and estimated market size and market growth including with respect to our long-term business strategy for quantum computing as a service (“Quantum Computing as a Service,” or “QCaaS”); |
• | the success of our partnerships and collaborations; |
• | our ability to accelerate our development of multiple generations of quantum processors; |
• | customer concentration and the risk that a significant portion of our revenue currently depends on contracts with the public sector; |
• | the outcome of any legal proceedings that may be instituted against us or others with respect to the Business Combination or other matters; |
• | our ability to execute on our business strategy, including monetization of our products; |
• | our financial performance, growth rate and market opportunity; |
• | our ability to maintain the listing of our common stock and public warrants on the Nasdaq Capital Market (“Nasdaq”), and the potential liquidity and trading of such securities; |
• | the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, our ability to grow and manage growth profitably, maintain relationships with customers and suppliers and retain our management and key employees; |
• | costs related to the Business Combination and operating as a public company; |
• | our ability to establish and maintain effective internal controls over financial reporting; |
• | changes in applicable laws or regulations; |
• | the possibility that we may be adversely affected by other economic, business, or competitive factors; |
• | our estimates of expenses and profitability; |
• | the evolution of the markets in which we compete; |
• | our ability to implement our strategic initiatives, expansion plans and continue to innovate our existing services; |
• | the expected use of proceeds of the Business Combination; |
• | the sufficiency of our cash resources and our ability to raise additional capital; |
• | unfavorable conditions in our industry, the global economy or global supply chain (including any supply chain impacts from the ongoing military conflict involving Russia and Ukraine), including inflation and financial and credit market fluctuations; |
• | changes in applicable laws or regulations; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors; |
• | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
• | our ability to expand or maintain our existing customer base; and |
• | the effect of COVID-19 on the foregoing. |
• | We are in our early stages and have a limited operating history, which makes it difficult to forecast our future results of operations. |
• | We have a history of operating losses and expect to incur significant expenses and continuing losses for the foreseeable future. |
• | Even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all. |
• | We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations and may need additional capital sooner than planned to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be sure that additional financing will be available. |
• | Our ability to use net operating loss carryforwards and other tax attributes may be limited in connection with the Business Combination or other ownership changes. |
• | We have not produced quantum computers with high qubit counts or at volume and face significant barriers in our attempts to produce quantum computers, including the need to invent and develop new technology. If we cannot successfully overcome those barriers, our business will be negatively impacted and could fail. |
• | Any future generations of hardware developed to demonstrate narrow quantum advantage and broad quantum advantage and the anticipated release of an 84 qubit system, 336 qubit system, a 1,000+ qubit system and 4,000+ qubit system, each of which is an important anticipated milestone for our technical roadmap and commercialization, may not occur on our anticipated timeline or at all. |
• | The quantum computing industry is competitive on a global scale and we may not be successful in competing in this industry or establishing and maintaining confidence in our long-term business prospects among current and future partners and customers. |
• | Our business is currently dependent upon our relationship with our cloud providers. There are no assurances that we will be able to commercialize quantum computers from our relationships with cloud providers. |
• | We depend on a limited number of customers for a significant percentage of our revenue and the loss or temporary loss of a major customer for any reason could harm our financial condition. |
• | A significant portion of our revenue depends on contracts with the public sector, and our failure to receive and maintain government contracts or changes in the contracting or fiscal policies of the public sector could have a material adverse effect on our business. |
• | We rely on access to high performance third party classical computing through public clouds, high performance computing centers and on-premises computing infrastructure to deliver performant quantum solutions to customers. We may not be able to maintain high quality relationships and connectivity with these resources which could make it harder for us to reach customers or deliver solutions in a cost-effective manner. |
• | We depend on certain suppliers to source products. Failure to maintain our relationship with any of these suppliers, or a failure to replace any supplier, could have a material adverse effect on our business, financial position, results of operations and cash flows. |
• | Our system depends on the use of certain development tools, supplies, equipment and production methods. If we are unable to procure the necessary tools, supplies and equipment to build our quantum systems, or are unable to do so on a timely and cost-effective basis, and in sufficient quantities, we may incur significant costs or delays which could negatively affect our operations and business. |
• | Even if we are successful in developing quantum computing systems and executing on our strategy, competitors in the industry may achieve technological breakthroughs which render our quantum computing systems obsolete or inferior to other products. |
• | We may be unable to reduce the cost of developing our quantum computers, which may prevent us from pricing our quantum systems competitively. |
• | The quantum computing industry is in its early stages and volatile, and if it does not develop, if it develops slower than we expect, if it develops in a manner that does not require use of our quantum computing solutions, if we encounter negative publicity or if our solution does not drive commercial engagement, the growth of our business will be harmed. |
• | If our computers fail to achieve quantum advantage, our business, financial condition and future prospects may be harmed. |
• | We could suffer disruptions, outages, defects and other performance and quality problems with our quantum computing systems, our production technology partners or with the public cloud, data centers and internet infrastructure on which we rely. |
• | We have, in the past, identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future. If we fail to establish and maintain effective control over financial reporting, it may adversely affect our ability to accurately and timely report our financial results, and may adversely affect investor confidence and business operations. |
• | System security and data protection breaches, as well as cyber-attacks, including state-sponsored attacks, could disrupt our operations, which may damage our reputation and adversely affect our business. |
• | Our failure to obtain, maintain and protect our intellectual property rights could impair our ability to protect and commercialize our proprietary products and technology and cause us to lose our competitive advantage. |
• | Delaware law, the Certificate of Incorporation and Bylaws contain certain provisions, including anti-takeover provisions, that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable. |
• | Our business will require significant amounts of capital to sustain operations. |
• | Our warrants are accounted for as liabilities. |
• | Sales of our common stock, or the perception of such sales, by us or the selling securityholders pursuant to this prospectus in the public market or otherwise could cause the market price for our common stock to decline and certain selling securityholders still may receive significant proceeds, and future issuances of securities may adversely affect us and our common stock and may be dilutive to existing stockholders. |
• | Our failure to meet the continued listing requirements of Nasdaq. |
• | Our warrants may be out of the money at the time they become exercisable and they may expire worthless. |
• | With the approval by the holders of at least 50% of the then-outstanding public warrants, we may amend the terms of the warrants in a manner that may be adverse to holders. |
Issuer |
Rigetti Computing, Inc. (f/k/a Supernova Partners Acquisition Company II, Ltd.). |
Shares of common stock offered by us |
Up to 19,354,059 shares of our common stock consisting of (i) 4,450,000 shares of common stock issuable upon exercise of the private placement warrants by holders thereof, (ii) 8,624,972 shares of common stock issuable upon exercise of the public warrants by holders thereof, and (iii) 6,279,087 shares of common stock issuable upon exercise of the Rigetti assumed warrants by holders thereof. |
Shares of common stock outstanding prior to exercise of all warrants and Rigetti assumed warrants |
113,820,970 shares (as of May 20, 2022). |
Shares of common stock outstanding assuming exercise of all warrants and Rigetti assumed warrants |
133,175,029 shares (based on total number of outstanding shares of common stock as of May 20, 2022). |
Exercise price of public warrants and private placement warrants |
$11.50 per share, subject to adjustment as described herein. |
Exercise price of Rigetti assumed warrants |
The weighted average exercise price of the Rigetti assumed warrants is $0.6628 per share. |
Use of proceeds |
We could potentially receive up to an aggregate of approximately $150.4 million from the exercise of the warrants and approximately $4.2 million from the exercise of Rigetti assumed warrants, assuming the exercise in full of all of the warrants and Rigetti assumed warrants for cash. We expect to use any net proceeds from the exercise of the warrants and Rigetti assumed warrants for general corporate purposes. We believe the likelihood that warrant holders will exercise their public warrants and private placement warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our common stock. If the trading price for our common stock is less than $11.50 per share, we believe holders of our public warrants and private warrants will be unlikely to exercise their warrants. See the section entitled “Use of Proceeds.” |
Shares of common stock offered by the selling securityholders |
We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, and aggregate of up to 96,941,181 shares of common stock, consisting of: |
• | 14,641,244 shares of common stock issued in the PIPE Financing; |
• | 8,625,000 Founder Shares (including 3,059,273 Sponsor Vesting Shares subject to vesting and forfeiture); |
• | 4,450,000 shares of common stock issuable upon the exercise of the private placement warrants; |
• | 2,446,716 shares of common stock issuable upon the exercise of Rigetti assumed warrants; |
• | 6,226,065 shares of common stock issuable upon the exercise of outstanding options; |
• | 6,288,369 shares of common stock issuable in connection with the vesting and settlement of outstanding restricted stock units; and |
• | 54,263,787 shares of common stock issued in connection with the Business Combination to certain of the selling securityholders. |
Warrants offered by the selling security holders |
Up to 4,450,000 private placement warrants. |
Redemption |
The public warrants and private placement warrants are redeemable in certain circumstances. See the section entitled “ Description of Securities—Warrants |
Use of proceeds |
We will not receive any of the proceeds from the sale of the shares of common stock or warrants by the selling securityholders. |
Lock-up agreements |
Certain of our securityholders are subject to certain restrictions on transfer until the termination of applicable lock-up periods. See the sections entitled “ Certain Relationships and Related Party Transactions—Sponsor Support Agreement Description of Our Securities—Lock-Up Provisions in Bylaws |
Market for common stock and public warrants |
Our common stock and public warrants are currently traded on Nasdaq under the symbols “RGTI” and “RGTIW,” respectively. |
Risk factors |
Before investing in our securities, you should carefully read and consider the information set forth in “ Risk Factors |
• | attract new customers and grow our customer base; |
• | maintain and increase the rates at which existing customers use our platform, sell additional products and services to our existing customers, and reduce customer churn; |
• | invest in our platform and product offerings; |
• | effectively manage organizational change; |
• | accelerate and/or refocus research and development activities; |
• | expand manufacturing and supply chain capacity; |
• | increase sales and marketing efforts; |
• | broaden customer-support and services capabilities; |
• | maintain or increase operational efficiencies; |
• | implement appropriate operational and financial systems; and |
• | maintain effective financial disclosure controls and procedures. |
• | limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions, or other general business purposes; |
• | require us to use a portion of our cash flow from operations to make debt service payments instead of other purposes, thereby reducing the amount of cash flow available for future working capital, capital expenditures, acquisitions, or other general business purposes; |
• | expose us to the risk of increased interest rates as following the consummation of our initial public offering borrowings under the Loan Agreement are subject to interest at the greater of (i) a floating per annum rate equal to 7.5% above the prime rate, or (ii) a fixed per annum rate equal to 11.0%, also paid on a monthly basis; |
• | limit our flexibility to plan for, or react to, changes in our business and industry; |
• | increase our vulnerability to the impact of adverse economic, competitive and industry conditions; and |
• | increase our cost of borrowing. |
• | large, well-established tech companies that generally compete across our products, including Quantinuum, Google, Microsoft, Amazon, Intel and IBM; |
• | large research organizations funded by sovereign nations such as China, Russia, Canada, Australia and the United Kingdom, and those in the European Union as of the date of this prospectus and we believe additional countries in the future; |
• | less-established public and private companies with competing technology, including companies located outside the United States; and |
• | new or emerging entrants seeking to develop competing technologies. |
• | Changes in government fiscal or procurement policies, or decreases in government funding available for procurement of goods and services generally, or for our federal government contracts specifically; |
• | Changes in government programs or applicable requirements; |
• | Restrictions in the grant of personnel security clearances to our employees; |
• | Ability to maintain facility clearances required to perform on classified contracts for U.S. federal government and foreign government agencies; |
• | Changes in the political environment, including before or after a change to the leadership within the government administration, and any resulting uncertainty or changes in policy or priorities and resultant funding; |
• | Changes in the government’s attitude towards the capabilities that we offer; |
• | Changes in the government’s attitude towards us as a company or our platforms; |
• | Appeals, disputes, or litigation relating to government procurement, including but not limited to bid protests by unsuccessful bidders on potential or actual awards of contracts to us or our partners by the government; |
• | The adoption of new laws or regulations or changes to existing laws or regulations; |
• | Budgetary constraints, including automatic reductions as a result of “sequestration” or similar measures and constraints imposed by any lapses in appropriations for the federal government or certain of its departments and agencies; |
• | Influence by, or competition from, third parties with respect to pending, new, or existing contracts with government customers; |
• | Changes in political or social attitudes with respect to security or data privacy issues; |
• | Potential delays or changes in the government appropriations or procurement processes, including as a result of events such as war, incidents of terrorism, natural disasters, and public health concerns or epidemics, such as the coronavirus pandemic; and |
• | Increased or unexpected costs or unanticipated delays caused by other factors outside of our control. |
• | our inability to enter into agreements with suppliers on commercially reasonable terms, or at all; |
• | difficulties of suppliers ramping up their supply of materials to meet our requirements; |
• | a significant increase in the price of one or more components, including due to industry consolidation occurring within one or more component supplier markets or as a result of decreased production capacity at manufacturers; |
• | any reductions or interruption in supply, including disruptions on our global supply chain as a result of the COVID-19 pandemic, which we have experienced, and may in the future experience or as a result of the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia (including as a result of disruptions of global shipping, the transport of products, energy supply, cybersecurity incidents and banking systems as well as of our ability to control input costs) or otherwise; |
• | financial problems of either manufacturers or component suppliers; |
• | significantly increased freight charges, or raw material costs and other expenses associated with our business; |
• | other factors beyond our control or which we do not presently anticipate, could also affect our suppliers’ ability to deliver components to us on a timely basis; |
• | a failure to develop our supply chain management capabilities and recruit and retain qualified professionals; |
• | a failure to adequately authorize procurement of inventory by our contract manufacturers; or |
• | a failure to appropriately cancel, reschedule or adjust our requirements based on our business needs. |
• | unexpected costs and errors in the localization of our platform and solutions, including translation into foreign languages and adaptation for local culture, practices and regulatory requirements; |
• | lack of familiarity and burdens of complying with foreign laws, legal standards, privacy and cybersecurity standards, regulatory requirements, tariffs and other barriers, and the risk of penalties to our customers and individual members of management or employees if our practices are deemed to not be in compliance; |
• | practical difficulties of enforcing intellectual property rights in countries with varying laws and standards and reduced or varied protection for intellectual property rights in some countries; |
• | an evolving legal framework and additional legal or regulatory requirements for data privacy and cybersecurity, which may necessitate the establishment of systems to maintain data in local markets, requiring us to invest in additional data centers and network infrastructure, and the implementation of additional employee data privacy documentation (including locally-compliant data privacy notice and policies), all of which may involve substantial expense and may cause us to need to divert resources from other aspects of our business, all of which may adversely affect our business; |
• | unexpected changes in regulatory requirements, taxes, trade laws, tariffs, export quotas, custom duties or other trade restrictions; |
• | difficulties in managing systems integrators and technology partners; |
• | differing technology standards; |
• | different pricing environments, longer sales cycles, longer accounts receivable payment cycles and difficulties in collecting accounts receivable; |
• | increased financial accounting and reporting burdens and complexities; |
• | difficulties in managing and staffing international operations including the proper classification of independent contractors and other contingent workers, differing employer/employee relationships and local employment laws; |
• | increased costs involved with recruiting and retaining an expanded employee population outside the United States through cash and equity-based incentive programs and unexpected legal costs and regulatory restrictions in issuing our shares to employees outside the United States; |
• | global political and regulatory changes that may lead to restrictions on immigration and travel for our employees; |
• | fluctuations in exchange rates that may decrease the value of our foreign-based revenue; |
• | potentially adverse tax consequences, including the complexities of foreign value added tax (or other tax) systems, restrictions on the repatriation of earnings, and transfer pricing requirements; and |
• | permanent establishment risks and complexities in connection with international payroll, tax and social security requirements for international employees. |
• | obtain expertise; |
• | obtain sales and marketing services or support; |
• | obtain equipment and facilities; |
• | develop relationships with potential future customers; and |
• | generate revenue. |
• | specialized disclosure and accounting requirements unique to government contracts; |
• | financial and compliance audits that may result in potential liability for price adjustments, recoupment of government funds after such funds have been spent, civil and criminal penalties, or administrative sanctions such as suspension or debarment from doing business with the U.S. government; |
• | public disclosures of certain contract and company information; and |
• | mandatory socioeconomic compliance requirements, including labor requirements, non-discrimination and affirmative action programs and environmental compliance requirements. |
• | Any intellectual property litigation to which we might become a party, or for which we are required to provide indemnification, regardless of the merit of the claim or our defenses, may require us to do one or more of the following: |
• | cease selling or using solutions or services that incorporate the intellectual property rights that allegedly infringe, misappropriate or violate the intellectual property of a third party; |
• | make substantial payments for legal fees, settlement payments or other costs or damages; |
• | obtain a license, which may not be available on reasonable terms or at all, to sell or use the relevant technology; |
• | redesign the allegedly infringing solutions to avoid infringement, misappropriation or violation, which could be costly, time-consuming or impossible; or |
• | indemnify third parties using our products or services. |
• | our ability to meet our technological milestones, including any delays; |
• | changes in the industries in which we and our customers operate; |
• | variations in our operating performance and the performance of our competitors in general; |
• | material and adverse impact of the COVID-19 pandemic or the ongoing military conflict between Russia and Ukraine and the related sanctions imposed against Russia on the markets and the broader global economy; |
• | actual or anticipated fluctuations in our quarterly or annual operating results; |
• | publication of research reports by securities analysts about us or our competitors or our industry; |
• | the public’s reaction to our press releases, our other public announcements and our filings with the SEC; |
• | our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market; |
• | additions and departures of key personnel; |
• | changes in laws and regulations affecting our business; |
• | commencement of, or involvement in, litigation involving the Company; |
• | changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; |
• | the volume of shares of our common stock available for public sale, including the significant percentage of shares of our common stock being offered for resale pursuant to this prospectus; |
• | the public’s response to press releases or other public announcements by us or third parties, including our filings with the SEC; |
• | guidance, if any, that we provide to the public, any changes in this guidance or our failure to meet this guidance, including with respect to our technical roadmap; |
• | the development and sustainability of an active trading market for our stock; |
• | actions by institutional or activist stockholders; |
• | changes in accounting standards, policies, guidelines, interpretations or principles; and |
• | other events or factors, including recessions, increases in inflation and interest rates, foreign currency fluctuations, international tariffs, social, political and economic risks, natural disasters acts of war (including the conflict involving Russia and Ukraine), terrorism or responses to such events. |
• | labor availability and costs for hourly and management personnel; |
• | profitability of our products, especially in new markets and due to seasonal fluctuations; |
• | changes in interest rates; |
• | impairment of long-lived assets; |
• | macroeconomic conditions, both nationally and locally; |
• | negative publicity relating to products we serve; |
• | changes in consumer preferences and competitive conditions; and |
• | expansion to new markets. |
• | may significantly dilute the equity interests of our investors; |
• | may subordinate the rights of holders of common stock if preferred stock is issued with rights senior to those afforded our common stock; |
• | could cause a change in control if a substantial number of shares of our common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and |
• | may adversely affect prevailing market prices for our common stock. |
• | providing for a classified board of directors with staggered, three-year terms; |
• | the ability of the Board to issue up to 10,000,000 shares of preferred stock, including “blank check” preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; |
• | provide that the authorized number of directors may be changed only by resolution of the Board; |
• | provide that, subject to the rights of the holders of any series of preferred stock, any individual director or directors may be removed only with cause by the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class; |
• | provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; |
• | require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission; |
• | provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice; |
• | provide that special meetings of our stockholders may be called by the chairperson of the Board, the chief executive officer or by the Board pursuant to a resolution adopted by a majority of the total number of authorized directors; and |
• | not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. |
• | result in us incurring substantial costs; |
• | affect our ability to timely file our periodic reports until the restatement is completed; |
• | divert the attention of our management and employees from managing our business; |
• | result in material changes to our historical and future financial results; |
• | result in investors losing confidence in our operating results; |
• | subject us to securities class action litigation; and |
• | cause our stock price to decline. |
Three Months Ended March 31, |
||||||||||||||||
2022 |
2021 |
$ Change |
% Change |
|||||||||||||
(In thousands) |
||||||||||||||||
Revenue: |
$ | 2,104 | $ | 2,360 | $ | (256 | ) | -11 | % | |||||||
Cost of revenue |
414 | 273 | 141 | 52 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total gross profit |
1,690 | 2,087 | (397 | ) | -19 | % | ||||||||||
Operating expenses: |
||||||||||||||||
Research and development |
12,449 | 6,934 | 5,515 | 80 | % | |||||||||||
Sales and marketing |
1,475 | 312 | 1,163 | 373 | % | |||||||||||
General and administrative |
11,560 | 2,521 | 9,039 | 359 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
25,484 | 9,767 | 15,717 | 161 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Loss from operations |
(23,794 | ) | (7,680 | ) | (16,114 | ) | 210 | % | ||||||||
|
|
|
|
|
|
|||||||||||
Other (expense) income, net: |
||||||||||||||||
Interest (expense) |
(1,205 | ) | (77 | ) | (1,128 | ) | nm | |||||||||
Change in fair value of warrant liabilities |
5,822 | — | 5,822 | nm | ||||||||||||
Change in fair value of earn-out liability |
9,634 | — | 9,634 | nm | ||||||||||||
Transaction cost |
(927 | ) | — | (927 | ) | nm | ||||||||||
Other income |
— | (30 | ) | 30 | -100 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other (expense) income, net |
13,324 | (107 | ) | 14,559 | ||||||||||||
Net loss before provision for income taxes |
(10,470 | ) | (7,787 | ) | (2,683 | ) | ||||||||||
Provision for income taxes |
— | — | — | |||||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (10,470 | ) | $ | (7,787 | ) | $ | (2,683 | ) | |||||||
|
|
|
|
|
|
• | a $3.6 million increase in employee related costs in the three months ended March 31, 2022 due to an increase in headcount and resulting wage costs of $1.5 million, a $0.5 million increase due to the increase in stock compensation expense, and a one-time cumulative recognition of previously deferred stock compensation expense of $1.6 million related to the satisfaction of the liquidity condition with respect to outstanding stock units recognized as a result of the close of the Business Combination; and |
• | a $1.9 million increase in material and software subscription costs due to continued and expanded investment in research and development efforts. |
• | a one-time cumulative recognition of previously deferred stock compensation expense of $6.9 million related to the satisfaction of the liquidity condition with respect to outstanding stock units recognized as a result of the close of the Business Combination; |
• | one-time transaction bonuses awarded to employees in connection with the closing of the Business Combination and associated taxes of $2.1 million; |
• | $1.7 million increase in stock compensation expense; |
• | $0.5 million due to increased legal, accounting costs related to enhanced public reporting requirements and other software acquisition costs; |
• | $0.2 million due to executive incentive plan related bonuses; and |
• | $0.4 million due to increased headcount-related wage costs to build and upgrade the resources to operate as a public company and to build out our information security team. |
11 Months Ended |
Year Ended |
|||||||||||||||
December 31, |
January 31, |
|||||||||||||||
2021 |
2021 |
$Change |
% Change |
|||||||||||||
( In thousands) |
||||||||||||||||
Revenue |
$ | 8,196 | $ | 5,543 | $ | 2,653 | 48 | % | ||||||||
Cost of revenue |
1,623 | 1,492 | 131 | 9 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total gross profit |
6,573 | 4,051 | 2,522 | 62 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development |
26,928 | 24,099 | 2,829 | 12 | % | |||||||||||
General and administrative |
11,299 | 13,158 | (1,859 | ) | -14 | % | ||||||||||
Sales and marketing |
2,475 | 1,886 | 589 | 31 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
40,702 | 39,143 | 1,559 | 4 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Loss from operations |
$ | (34,129 | ) | $ | (35,092 | ) | $ | 963 | -3 | % | ||||||
|
|
|
|
|
|
|||||||||||
Other (expense) income, net: |
||||||||||||||||
Gain on extinguishment of debt |
— | 8,914 | (8,914 | ) | nm | |||||||||||
Change in fair value of warrant liability |
(1,664 | ) | — | (1,664 | ) | nm | ||||||||||
Interest expense |
(2,465 | ) | (52 | ) | (2,413 | ) | nm | |||||||||
Interest income |
10 | 60 | (50 | ) | -83 | % | ||||||||||
Other income |
7 | 42 | (35 | ) | -83 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other (expense) income, net |
(4,112 | ) | 8,964 | (13,076 | ) | |||||||||||
Net loss before provision for income taxes |
(38,241 | ) | (26,128 | ) | (12,113 | ) | ||||||||||
Provision for income taxes |
— | — | — | |||||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (38,241 | ) | $ | (26,128 | ) | $ | (12,113 | ) | |||||||
|
|
|
|
|
|
Total |
Short-Term |
Long-Term |
||||||||||
Financing obligations |
$ | 30,043 | $ | 2,365 | $ | 27,678 | ||||||
Operating lease obligations |
4,180 | 1,314 | 2,866 | |||||||||
|
|
|
|
|
|
|||||||
Total |
$ | 34,223 | $ | 3,679 | $ | 30,544 | ||||||
|
|
|
|
|
|
Three Months Ended |
11 Months Ended |
Year Ended |
||||||||||||||
March 31, |
December 31, |
January 31, |
||||||||||||||
2022 |
2021 |
2021 |
2021 |
|||||||||||||
Net cash used in operating activities |
$ | (15,721 | ) | $ | (5,795 | ) | $ | (29,043 | ) | $ | (30,067 | ) | ||||
Net cash used in investing activities |
(2,836 | ) | (1,488 | ) | (7,008 | ) | (4,400 | ) | ||||||||
Net cash provided by financing activities |
213,445 | 12,026 | 25,582 | 56,289 |
• | one-time transaction bonuses awarded to employees in connection with the closing of the Business Combination and related taxes of $2.1 million; |
• | increase in headcount and payroll related costs of $2.6 million as a result of investments in research and development efforts combined with upgrading internal and external resources to operate as a public company; |
• | $1.1 million due to expanded material and software acquisition costs associated with research and development activities; |
• | $1.0 million in additional interest costs related to increased borrowing amounts associated with the Loan Agreement; and |
• | prepayment of insurance premium for directors and officers of $3.0 million. |
• | Create high performance quantum computing systems through full-stack product development. Fab-1. |
• | Leverage cloud to provide broad access to our quantum computers. |
• | Develop deep partnerships that accelerate the development and commercialization of quantum computing. |
• | Advance our technology leadership position . |
algorithm and application developers to rapidly innovate, invent, engineer and commercialize our quantum computing technologies. We have also developed numerous proprietary technologies required to create quantum computing chips, quantum computer systems, software and cloud-based services and we rigorously protect our unique intellectual property through a portfolio of 145 patents issued and pending. We intend to continue deeply investing in finding and fostering the talent required to remain at the forefront of quantum computing innovation, while protecting our growing base of intellectual property. |
• | Enabling customers to access Rigetti QPUs through a broad range of quantum application software, development frameworks and algorithm libraries; |
• | Providing software and algorithm developers with the performance and fine-grained control required to expedite a new era of computational breakthroughs; and |
• | Facilitating the implementation of high performance public and private clouds with ultra-low latency connectivity between classical hardware and Rigetti QPUs. |
• | Fermi National Accelerator Laboratory, or Fermilab, and the U.S. DOE’s Superconducting Quantum Materials and Systems Center (“SQMS”), to advance the development of scalable and high performance quantum processors; |
• | DARPA and National Aeronautics and Space Administration (“NASA”) to create quantum computing systems, software and algorithms for optimization applications; and |
• | Innovate UK, as part of the British government’s effort to accelerate commercialization of quantum computing in the United Kingdom and to pursue practical applications in machine learning, molecular simulation and financial optimization. |
• | healthcare – for medical image analysis used to detect and categorize tumors and predict their growth; |
• | drug discovery – for generating molecular structure candidates for medicines to target or cure diseases; |
• | banking – for creating models that can detect financial fraud based upon predictive patterns rather than rules determined by previously observed behaviors; and |
• | defense and intelligence – for reliably converting low resolution satellite imagery into high resolution photography. |
• | enterprise-sized organizations working on quantum-assisted breakthroughs in applications areas like drug discovery, network optimization, financial modeling, weather forecasting and fusion energy with organizations like Astex Pharmaceuticals, Deloitte, NASA, Nasdaq, Standard Chartered Bank, the U.S. DOE and certain military branches within the U.S. Department of Defense; |
• | materials science researchers and quantum algorithm developers at renowned laboratories like Fermilab, Lawrence Livermore National Laboratory, MIT Lincoln Laboratory, NASA Quantum Artificial Intelligence Laboratory and ORNL; |
• | quantum-focused software and algorithm companies like 1Qbit, Phasecraft, Riverlane, Q-CTRL and Zapata; |
• | Cloud service providers like Amazon Web Services, Microsoft, and Strangeworks; and |
• | We also enter into multi-year technology development partnerships with organizations that possess specialized technical expertise and strong interests in advancing the development of quantum computing (as referenced in Business – Key Technology Development Partnerships |
1. | United in our purpose. |
2. | Embrace grand challenges. |
3 . |
Build for tomorrow. |
4. | Act with integrity. |
5. | Evolve and grow. |
6. | Magic through mastery. |
Name |
Age |
Position | ||||
Executive Officers |
||||||
Chad Rigetti | 43 | President, Chief Executive Officer and Director | ||||
Brian Sereda | 61 | Chief Financial Officer | ||||
Rick Danis | 52 | General Counsel and Corporate Secretary | ||||
Mike Harburn | 52 | Chief Technology Officer | ||||
Greg Peters | 62 | Chief Revenue Officer | ||||
Non-Employee Directors |
||||||
Alissa Fitzgerald | 52 | Director | ||||
Gen. Peter Pace | 76 | Director | ||||
Ray Johnson | 66 | Director | ||||
David Cowan | 55 | Director | ||||
Cathy McCarthy | 74 | Director | ||||
Michael Clifton | 42 | Director | ||||
H. Gail Sandford | 58 | Director |
• | the Class I directors are Chad Rigetti, Ray Johnson and H. Gail Sandford, and their terms will expire at the annual meeting of stockholders to be held in 2023; |
• | the Class II directors are Alissa Fitzgerald, Gen. Peter Pace and David Cowan, and their terms will expire at the annual meeting of stockholders to be held in 2024; and |
• | the Class III directors are Cathy McCarthy and Michael Clifton and their terms will expire at the annual meeting of stockholders to be held in 2025. |
• | oversee our accounting and financial reporting processes, systems of internal control, financial statement audits and the integrity of our financial statements; |
• | manage the selection, engagement terms, fees, qualifications, independence, and performance of the registered public accounting firms engaged as our independent outside auditors for the purpose of preparing or issuing an audit report or performing audit services (the “ Auditors |
• | maintain and foster an open avenue of communication with our management, internal audit group (if any) and Auditors; |
• | review any reports or disclosures required by applicable law and stock exchange listing requirements; |
• | oversee the design, implementation, organization and performance of our internal audit function (if any); |
• | help our Board oversee our legal and regulatory compliance, including risk assessment; |
• | oversee our technology security and data privacy programs; |
• | Prepare the audit committee report required by the SEC to be included in our annual proxy statement, and |
• | provide regular reports and information to the Board. |
• | help the Board oversee our compensation policies, plans and programs with a goal to attract, incentivize, retain and reward top quality executive management and employees; |
• | review and determine the compensation to be paid to our executive officers and directors; |
• | when required, review and discuss with management our compensation disclosures in the “Compensation Discussion and Analysis” section of our annual reports, registration statements, proxy statements or information statements filed with the SEC; |
• | when required, prepare and review the Committee report on executive compensation included in our annual proxy statement; and |
• | review and ensure our talent management strategies are aligned to best practices and ensure we attract, retain and develop top talent. |
• | help the Board oversee our corporate governance functions and develop, update as necessary and recommend to the Board the governance principles applicable to Rigetti; |
• | identify, evaluate and recommend and communicate with candidates qualified to become Board members or nominees for directors of the Board consistent with criteria approved by the Board; and |
• | make other recommendations to the Board relating to the directors of Rigetti. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for any unlawful payment of dividends or redemption of shares; or |
• | for any breach of a director’s duty of loyalty to the corporation or our stockholders. |
• | Chad Rigetti, Rigetti’s President and CEO; |
• | Brian Sereda, Rigetti’s Chief Financial Officer; and |
• | Taryn Naidu, Rigetti’s Former Chief Operating Officer |
Name, Principal Position |
Fiscal Year |
Salary(1) |
Bonus(2) |
Stock Awards(3) |
Option Awards(4) |
Non-Equity Incentive Plan Compensation(5) |
All Other Compensation(6) |
Total |
||||||||||||||||||||||||
Chad Rigetti |
2021 | $ | 320,833 | $ | 1,300 | $ | 3,810,571 | — | $ | 56,000 | $ | 584 | 4,189,288 | |||||||||||||||||||
President and CEO |
2020 | $ | 276,340 | $ | 3,000 | — | $ | 376,059 | — | $ | 608 | $ | 656,007 | |||||||||||||||||||
Brian Sereda(7) |
2021 | $ | 121,875 | $ | 75,000 | $ | 3,825,049 | — | $ | 19,500 | $ | 72 | $ | 4,041,496 | ||||||||||||||||||
Chief Financial Officer |
||||||||||||||||||||||||||||||||
Taryn Naidu(8) |
2021 | $ | 258,098 | — | $ | 1,378,794 | — | $ | 45,540 | $ | 4,343 | $ | 1,686,775 | |||||||||||||||||||
Former Chief Operating Officer |
2020 | $ | 228,357 | $ | 3,000 | — | $ | 85,798 | — | $ | 10,420 | $ | 327,575 |
(1) | Salary amounts represent actual amounts earned during fiscal year 2021. See “—Narrative Disclosure to Summary Compensation Table—Base Salaries |
(2) | This column reflects amounts awarded as discretionary bonuses in fiscal year 2021 and fiscal year 2020. |
(3) | This column reflects the aggregate grant date fair value of the restricted stock units granted to the named executive officer during fiscal year 2021 under the 2013 Plan (as defined below). The aggregate grant date fair value is computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our financial statements included elsewhere in this prospectus. In accordance with ASC Topic 718, recognition of compensation expense is deferred until consummation of the Business Combination. This amount does not reflect the actual economic value that may be realized by the named executive officer. |
(4) | This column reflects the aggregate grant date fair value of the option awards granted during fiscal year 2020 and the incremental fair value of option awards modified in fiscal year 2020 computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. The amounts reported include the effect of the |
Repricing (as defined below) in May 2020 of stock options held by employees, including the named executive officers, whereby the exercise price per share of each stock option was lowered to $0.214 (our fair market value per share on the date of the Repricing). Please see the description of the Repricing under “Equity-Based Incentive Awards” below. The incremental grant date fair value of the Repricing was $890 and $15,880 for Dr. Rigetti and Mr. Naidu, respectively. |
(5) | See “ —Narrative to Summary Compensation Table—Non-Equity Incentive Plan Compensationnon-equity incentive plan compensation represent amounts earned for the fiscal years presented, whether or not actually paid during such year. |
(6) | This column reflects the aggregate value of other categories of payment, consisting of (i) for Dr. Rigetti, $584 and $608 for life insurance premiums for fiscal year 2021 and fiscal year 2020, respectively; (ii) for Mr. Naidu, $552 for life insurance premiums for each of fiscal year 2021 and fiscal year 2020, $8,305 for temporary housing for fiscal year 2020 and $3,791 and $1,563 for professional membership fees for fiscal year 2021 and fiscal year 2020, respectively; and (iii), for Mr. Sereda, $72 for life insurance premiums for fiscal year 2021. |
(7) | Mr. Sereda joined Rigetti as Chief Financial Officer in August 2021. Mr. Sereda was not a named executive officer for fiscal year 2020. |
(8) | On April 18, 2022, Mr. Naidu’s employment with Rigetti terminated. |
Option Awards |
Stock Awards |
|||||||||||||||||||||||||||
Name |
Grant Date |
Number of Securities Underlying Unexercised Options (#) Exercisable |
Number of Securities Underlying Unexercised Options (#) Unexercisable |
Option Exercise Price |
Option Expiration Date |
Equity incentive plan awards: Number of Unearned shares, units or other rights that have not vested(#)(1) |
Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested($)(2) |
|||||||||||||||||||||
Chad Rigetti |
07/13/2016 | 2,242 | 118 | (3) | $ | 0.272 | 07/12/2026 | — | — | |||||||||||||||||||
05/16/2017 | 1,062 | 354 | (4) | $ | 0.272 | 05/15/2027 | — | — | ||||||||||||||||||||
01/20/2021 | 393 | — | $ | 0.272 | 1/19/2031 | — | — | |||||||||||||||||||||
12/14/2017 | 944 | — | $ | 0.272 | 12/13/2027 | — | — | |||||||||||||||||||||
04/04/2018 | 1,023 | — | $ | 0.272 | 04/03/2028 | — | — | |||||||||||||||||||||
07/11/2018 | 786 | — | $ | 0.272 | 07/10/2028 | — | — | |||||||||||||||||||||
09/26/2018 | 1,495 | — | $ | 0.272 | 09/25/2028 | — | — | |||||||||||||||||||||
01/29/2019 | 708 | — | $ | 0.272 | 01/28/2029 | — | — | |||||||||||||||||||||
01/29/2019 | 629 | — | $ | 0.272 | 01/28/2029 | — | — | |||||||||||||||||||||
10/30/2019 | 393 | — | $ | 0.272 | 10/29/2029 | — | — | |||||||||||||||||||||
10/30/2019 | 472 | — | $ | 0.272 | 10/29/2029 | — | — | |||||||||||||||||||||
10/30/2019 | 865 | — | $ | 0.272 | 10/29/2029 | — | — | |||||||||||||||||||||
05/22/2020 | 2,061,218 | 1,410,308 | (5) | $ | 0.272 | 05/31/2030 | — | — | ||||||||||||||||||||
01/20/2021 | 393 | — | $ | 0.272 | 01/19/2031 | — | — | |||||||||||||||||||||
04/21/2021 | — | — | — | — | 1,044,905 | (6) | $ | 10,752,072 | ||||||||||||||||||||
Taryn Naidu(11) |
04/04/2019 | 86,568 | 70,829 | (7) | $ | 0.272 | 04/03/2019 | — | — | |||||||||||||||||||
05/22/2020 | 321,088 | 325,944 | (8) | $ | 0.272 | 05/01/2030 | — | — | ||||||||||||||||||||
04/21/2021 | — | — | — | — | 378,082 | (9) | $ | 3,890,464 | ||||||||||||||||||||
Brian Sereda |
08/18/2021 | — | — | — | — | 1,048,875 | (10) | $ | 10,792,924 |
(1) | Represents RSUs that vest based on the satisfaction of both a service-based vesting condition and a liquidity-based vesting condition, which is satisfied as described above under “ Narrative Disclosure to Summary Compensation Table— Equity-Based Incentive Awards |
(2) | Represents the market value of RSUs as of December 31, 2021 based on the RSUs that were assumed and converted into a Rigetti assumed RSUs to acquire shares of common stock at the Exchange Ratio and based on the closing price of Supernova Class A ordinary shares of $10.29 per share on December 31, 2021. |
(3) | Twenty percent (20%) of the shares underlying this option vested on April 1, 2017, and the remaining shares underlying this option vest in 60 equal monthly installments on the last calendar day of the month, subject to continued service at each vesting date. Please see “ —Employment Arrangements with Executive Officers |
(4) | Twenty percent (20%) of the shares underlying this option vested on April 1, 2018, and the remaining shares underlying this option vest in 48 equal monthly installments on the last calendar day of the month, subject to continued service at each vesting date. Please see “ —Employment Arrangements with Executive Officers |
(5) | 867,881 of the shares underlying this option were vested as of the vesting commencement date on May 22, 2020, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each month following the vesting commencement date (February 18, 2020) on the same day of the month as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to Dr. Rigetti’s continuing to be a Service Provider (as defined in the 2013 Plan) through each such date, subject to continued service at each vesting date. Please see “— Employment Arrangements with Executive Officers |
(6) | The RSUs have a dual vesting condition whereby vesting monthly over four-year term so long as the employee retains their status with Rigetti. There is an additional liquidity-event vesting requirement that is defined as a change in control, a successful IPO or a successful merger with a SPAC, which was satisfied upon the Closing. Therefore, 28,252 of Dr. Rigetti’s RSU’s vested upon the Closing. |
(7) | Twenty percent (20%) of the shares underlying this option vested on March 18, 2020, and the remaining shares underlying this option vest in 48 equal monthly installments on the last calendar day of the month, subject to continued service at each vesting date. Please see “— Employment Arrangements with Executive Officers |
(8) | 45,292 of the shares underlying this option were vested as of the vesting commencement date on February 18, 2020, and one forty-eighth (1/48) of the remainder of the shares subject to this option vest each month following the vesting commencement date on the same day of the month as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to Mr. Naidu’s continuing to be a Service Provider (as defined in the 2013 Plan) through each such date, subject to continued service at each vesting date. Please see “— Employment Arrangements with Executive Officers |
(9) | The RSUs have dual vesting conditions, a time-based vesting requirement and a liquidity-event vesting requirement. The time-based vesting requirement is met monthly over a four-year term so long as the employee retains their status with Rigetti. The liquidity-event vesting requirement that is defined as a change in control, a successful IPO or a successful merger with a SPAC, which was satisfied upon the Closing. Therefore, 78,766 of Mr. Naidu’s RSUs vested upon the Closing. |
(10) | The RSUs have dual vesting conditions, a time-based vesting requirement and a liquidity-event vesting requirement. The time-based vesting requirement is met monthly over a four-year term with a 1-year cliff, so long as the employee retains their status with Rigetti. The liquidity event vesting requirement is defined as a change in control, a successful IPO or a successful merger with a SPAC which was satisfied upon the Closing. However, none of Mr. Sereda’s RSUs vested upon the Closing because the first-year anniversary of the grant date was August 18, 2022. |
(11) | On April 18, 2022, Mr. Naidu’s employment with Rigetti terminated. |
Name |
Number of Shares of Rigetti Class A common stock Subject to RSUs |
Grant Date |
Vesting Commencement Date |
Time Based Vesting Schedule |
||||||||||||
Chad T. Rigetti |
2,174,346 | January 25, 2022 | January 25, 2022 | (A | ), (C) | |||||||||||
Taryn Naidu(1) |
338,199 | January 25, 2022 | January 25, 2022 | (A | ), (C) | |||||||||||
Rick Danis |
125,315 | January 25, 2022 | January 25, 2022 | (A | ), (C) | |||||||||||
Brian Sereda |
6,689 | January 25, 2022 | January 25, 2022 | (B | ), (C) | |||||||||||
Michael Harburn |
157,650 | January 25, 2022 | January 25, 2022 | (B | ), (C) | |||||||||||
David Rivas |
101,283 | January 25, 2022 | January 25, 2022 | (A | ), (D) | |||||||||||
Mandy Birch(1) |
151,899 | January 25, 2022 | January 25, 2022 | (A | ), (D) |
(A) | The RSUs are subject to the time-based vesting requirement and liquidity-event vesting requirement described in the summary of material terms of the 2013 Plan under “2013 Plan” below (the Closing of the Business Combination will satisfy the liquidity-event requirement). Time-based vesting will occur in accordance with the following schedule (subject to the individual continuing as a Service Provider (as defined in the 2013 Plan) on each such vesting date): (i) 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) at the end of each month following the vesting commencement date over a period of 12 months and (ii) the remaining 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) at the end of each month following the vesting commencement |
date over a period of four years. Prongs (i) and (ii) of the time-based vesting will occur concurrently, such that, at the end of the 12-month period immediately following the vesting commencement date, 62.5% of the total number of RSUs will have vested (subject to Participant continuing as a Service Provider on such vesting date). This vesting schedule will also apply to employees who have served in their roles for at least two years before the grant date. |
(B) | The RSUs are subject to the time-based vesting requirement and liquidity-event vesting requirement described in the summary of material terms of the 2013 Plan under “2013 Plan” below (the Closing of the Business Combination will satisfy the liquidity-event requirement). Time-based vesting will occur in accordance with the following schedule (subject to the individual continuing as a Service Provider (as defined in the 2013 Plan) on each such vesting date): one-forty eighth (1/48th) of the total number of RSUs (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting each month following the vesting commencement date over a period of four years. This vesting schedule will also apply to employees For individuals who have served in their roles for less than two years as of the grant date. |
(C) | After satisfaction of the liquidity-event vesting requirement, in the event of a Change in Control (as defined in the 2013 Plan), 100% of the then unvested shares subject to the RSU grant shall vest immediately prior to the consummation of the Change in Control. |
(D) | After satisfaction of the liquidity-event vesting requirement, in the event of a Change in Control (as defined in the 2013 Plan), 50% of the then unvested shares subject to the RSU grant shall vest immediately prior to the consummation of the Change in Control, with such acceleration to be applied on a pro-rata basis with respect to each remaining vesting tranche. |
(1) | Mr. Naidu and Ms. Birch are no longer employed by Rigetti. |
Name |
Transaction Cash Bonus |
|||
Chad Rigetti |
$ | 400,000 | ||
Taryn Naidu |
$ | 400,000 | ||
Rick Danis |
$ | 350,000 | ||
Brian Sereda |
$ | 25,000 |
Name |
Number of Rigetti Stock Awards |
|||
Chad Rigetti |
45,000 | |||
Taryn Naidu (1) |
45,000 | |||
Brian Sereda |
5,000 | |||
Rick Danis |
25,000 |
(1) | On April 18, 2022, Mr. Naidu’s employment with Rigetti terminated. |
Name |
Number of Rigetti Alignment RSUs |
Rigetti Alignment RSUs Vesting |
Number of 2022 Rigetti Annual RSUs |
2022 Rigetti Annual RSUs Vesting |
||||||||||||
Chad Rigetti |
2,857,444 | (A | ), (C) | 334,700 | (B | ), (C) | ||||||||||
Taryn Naidu (1) |
444,450 | (A | ), (C) | 161,300 | (B | ), (C) | ||||||||||
Rick Danis |
164,685 | (A | ), (C) | 102,800 | (B | ), (C) | ||||||||||
Brian Sereda |
8,791 | (B | ), (C) | 128,600 | (B | ), (D) | ||||||||||
Michael Harburn |
207,178 | (B | ), (C) | 107,900 | (B | ), (D) |
(A) | Time-based vesting will occur in accordance with the following schedule (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on each such vesting date): (i) 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 12 months and (ii) the remaining 50% of the total number of RSUs will vest in substantially equal installments (rounded down, except for the final scheduled vesting installment) on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 48 months. Prongs (i) and (ii) of the time-based vesting will occur concurrently, such that, at the end of the 12-month period immediately following the Vesting Commencement Date, 62.5% of the total number of RSUs will have vested (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on such vesting date). This vesting schedule will also apply to employees who have served in their roles for at least two years before the grant date. |
(B) | Time-based vesting will occur in accordance with the following schedule (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on each such vesting date): one-forty eighth (1/48th) of the total number of RSUs (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 48 months. This vesting schedule will also apply to employees who have served in their roles for less than two years as of the grant date. |
(C) | In the event of a Change in Control (as defined in the 2022 Plan), 100% of the then unvested shares subject to the RSUs shall vest immediately prior to the consummation of the Change in Control. |
(D) | In the event of a Change in Control (as defined in the 2022 Plan), 50% of the then unvested shares subject to the RSUs shall vest immediately prior to the consummation of the Change in Control with such acceleration to be applied on a pro-rata basis with respect to each remaining vesting tranche. |
(E) | Time-based vesting will occur in accordance with the following schedule (subject to the individual’s Continuous Service (as defined in the 2022 Plan) on each such vesting date): one-forty eighth (1/48th) of the total number of RSUs (rounded down, except for the final scheduled vesting installment) will satisfy time-based vesting on the last day of each calendar month beginning with the month in which the Vesting Commencement Date occurs and over a period of 48 months. |
(1) | On April 18, 2022, Mr. Naidu’s employment with Rigetti terminated. |
Name |
Cash(1) |
Stock Awards ($)(2) |
Option Awards ($) |
All Other Compensation |
Total ($) |
|||||||||||||||
Peter Pace |
$ | — | $ | — | $ | — | — | — | ||||||||||||
Alissa Fitzgerald |
$ | — | $ | — | $ | — | — | — | ||||||||||||
Ray Johnson |
$ | — | $ | — | $ | — | — | — | ||||||||||||
Cathy McCarthy |
$ | — | $ | 1,076,250 | $ | — | — | $ | 1,076,250 |
(1) | None of the non-employee directors received cash compensation for their service as a director during the fiscal year ended December 31, 2021. |
(2) | This column reflects the aggregate grant date fair value of the restricted stock units granted to the director during fiscal year 2021 under the 2013 Plan. The aggregate grant date fair value is computed in accordance with ASC Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in the notes to our financial statements included elsewhere in this prospectus. In accordance with ASC Topic 718, recognition of compensation expense is deferred until consummation of the Business Combination. This amount does not reflect the actual economic value that may be realized by the director. |
Name |
Shares Underlying Options Outstanding (Vested) at Fiscal Year End |
Shares Underlying Options Outstanding (Unvested) at Fiscal Year End |
Unvested Stock Awards at Fiscal Year End |
|||||||||
Peter Pace |
141,370 | 153,750 | — | |||||||||
Alissa Fitzgerald |
126,731 | 168,388 | — | |||||||||
Ray Johnson |
78,800 | 216,320 | — | |||||||||
Cathy McCarthy |
— | — | 295,120 |
• | arrange for the assumption or substitution of a stock award by a surviving or acquiring corporation; |
• | terminate the stock awards; |
• | accelerate the vesting of the stock award and, to the extent the administrator determines, provide for termination if not exercised (if applicable) at or before the effective time of the merger or change in control; |
• | terminate or cancel or arrange for the termination or cancellation of the stock award, to the extent not vested or not exercised before the effective time of the transaction; or |
• | terminate the Award in exchange for an amount of cash and/or property equal to the amount that would have been attained upon the exercise of such Award or realization of the participant’s rights as of the date of the occurrence of the transaction or the replacement of such award with other rights or property selected by the administrator in its sole discretion; |
• | the amounts involved exceeded or will exceed $120,000; and |
• | any of our directors, executive officers or holders of more than 5% of the company’s capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. |
• | the risks, costs, and benefits to us; |
• | the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; |
• | the terms of the transaction; |
• | the availability of other sources for comparable services or products; and |
• | the terms available to or from, as the case may be, unrelated third parties. |
• | each person known by the Company to be the beneficial owner of more than 5% of outstanding shares of common stock; |
• | each of the Company’s named executive officers, including its former Chief Operating Officer, and directors; |
• | all executive officers and directors of the Company as a group, excluding its former Chief Operating Officer. |
Name of Beneficial Owner (1) |
Number of Shares of Common Stock Beneficially Owned |
% of Ownership |
||||||
Directors and Named Executive Officers |
||||||||
Chad Rigetti (2) |
7,468,310 | 6.4 | % | |||||
Taryn Naidu (3) |
817,371 | * | ||||||
Brian Sereda (4) |
696 | * | ||||||
Gen. Peter Pace (5) |
295,120 | * | ||||||
David Cowan (6) |
— | — | ||||||
Alissa Fitzgerald (7) |
216,903 | * | ||||||
Ray Johnson (8) |
199,040 | * | ||||||
Cathy McCarthy (9) |
73,780 | * | ||||||
Michael Clifton (10)(11) |
62,500 | * | ||||||
H. Gail Sandford |
— | — | ||||||
All executive officers and directors as a group (12 persons) |
8,948,515 | 7.6 | % | |||||
Five Percent Holders |
||||||||
Supernova Partners II LLC (11) |
12,868,000 | 10.9 | % | |||||
Entities affiliated with Bessemer Venture Partners (12) |
21,582,218 | 19.0 | % | |||||
AVG Entities (13) |
7,597,642 | 6.6 | % | |||||
Insurance Company of the West (14) |
9,178,816 | 8.1 | % |
* | Less than 1% |
(1) | Unless otherwise noted, the mailing address of each of those listed in the table above is 775 Heinz Avenue, Berkeley, CA, 94710. |
(2) | Consists of 4,144,913 shares of common stock held by Dr. Rigetti, and 3,323,397 shares of common stock issuable upon the exercise or settlement of options or restricted stock unit awards held by Dr. Rigetti which are exercisable or vest within 60 days of May 20, 2022. |
(3) | Consists of 204,960 shares of common stock held by Mr. Naidu, the former Chief Operating Officer of Rigetti, or his affiliated entity AlphaNuma LLC, and 612,411 shares of common stock issuable upon the exercise or settlement of options, Rigetti assumed warrants or restricted stock unit awards which are exercisable or vest as of April 18, 2022, the date Mr. Naidu’s employment with Rigetti terminated. |
(4) | Consists of 696 shares of common stock issuable upon the settlement restricted stock unit awards held by Mr. Sereda which vest within 60 days of May 20, 2022. |
(5) | Consists of 295,120 shares of common stock held by Gen. Pace. |
(6) | David Cowan, a member of the Rigetti Board, is a partner at Bessemer Venture Partners. Mr. Cowan disclaims beneficial ownership interest of the securities held by the Bessemer Entities (as defined below) referred to in footnote 12 below, except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in the Bessemer Entities. |
(7) | Consists of 216,903 shares of common stock issuable upon the exercise or settlement of options or restricted stock unit awards held by Ms. Fitzgerald which are exercisable or vest within 60 days of May 20, 2022. |
(8) | Consists of 22,788 shares of common stock held by Mr. Johnson, and 176,252 shares of common stock issuable upon the exercise or settlement of options or restricted stock unit awards held by Mr. Johnson which are exercisable or vest within 60 days of May 20, 2022. |
(9) | Consists of 73,780 shares of common stock issuable upon the exercise or settlement of options or restricted stock unit awards held by Ms. McCarthy which are exercisable or vest within 60 days of May 20, 2022. |
(10) | Consists of 62,500 shares of common stock purchased in the PIPE Financing. |
(11) | Supernova Sponsor holds 8,418,000 shares of common stock and 4,450,000 shares underlying private placement warrants held by Supernova Sponsor, which are exercisable for shares of common stock commencing 30 days after the closing of the Business Combination. Supernova Sponsor is governed by a board of managers consisting of four managers: Spencer M. Rascoff, Alexander M. Klabin, Robert D. Reid and Michael S. Clifton. Each manager has one vote, and the approval of a majority of the managers is required to approve any action of Supernova Sponsor. Under the so-called “rule of three,” if voting and dispositive decisions regarding an entity’s securities are made by three or more individuals, and a voting or dispositive decision requires the approval of at least a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity’s securities. Based upon the foregoing analysis, no director of Supernova Sponsor exercises voting or dispositive control over any of the securities held by Supernova Sponsor, even those in which he or she directly holds a pecuniary interest. Accordingly, none of them will be deemed to have or share beneficial ownership of such shares. Includes 2,479,000 Sponsor Vesting Shares that became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days, and (ii) 580,273 Sponsor Vesting Shares held by the Sponsor Holders became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days. Any such shares held by the Sponsor Holders that remain unvested after the fifth anniversary of the Closing will be forfeited. The address for Supernova Sponsor is 4301 50th Street NW, Suite 300 PMB 1044, Washington, D.C. 20016. |
(12) | Consists of (i) 9,481,710 shares of common stock held by Bessemer Venture Partners X Institutional L.P., or Bessemer Institutional, and 10,100,508 shares of common stock held by Bessemer Venture Partners X L.P., or Bessemer X, and together with Bessemer Institutional, the Bessemer Entities, and (ii) 968,400 shares of common stock purchased by Bessemer Institutional and 1,031,600 shares of common stock purchased by Bessemer X in the PIPE Financing. Deer X & Co. L.P., or Deer X L.P., is the general partner of the Bessemer Entities. Deer X & Co. Ltd., or Deer X Ltd., is the general partner of Deer X L.P. Adam Fisher, Robert P. Goodman, David Cowan, Jeremy Levine, Byron Deeter, Ethan Kurzweil, Alex Ferrara, Brian Feinstein and Stephen Kraus are the directors of Deer X Ltd. and hold the voting and dispositive power for the Bessemer Entities. Investment and voting decisions with respect to the securities held by the Bessemer Entities are made by the directors of Deer X Ltd. acting as an investment committee. Mr. Cowan disclaims beneficial ownership interest of the securities of the Company held by the Bessemer Entities except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in the Bessemer Entities. The address for the Bessemer Entities is c/o Bessemer Venture Partners, 1865 Palmer Avenue, Suite 104, Larchmont, NY 10538. |
(13) | Consists of (i) 772,613 shares of common stock held by AVG - BIV Rigetti Trust1 2020, 906,446 shares of common stock held by AVG - BIV Rigetti Trust2 2020, 5,344,241 shares of common stock held by AVG - BIV Rigetti Trust3 2020 and 29,429 shares of common stock held by AVGF-BIV 2 Rigetti 2017, LLC, (ii) 100,000 shares of common stock purchased by AVG - BIV Rigetti Trust3 2020 in the PIPE Financing and (iii) 444,913 of common stock issuable upon exercise of Rigetti assumed warrants held by AVG - BIV Rigetti Trust1 2020, AVG - BIV Rigetti Trust2 2020 and AVG - BIV Rigetti Trust3 2020 that are exercisable as of or within 60 days of May 20, 2022. |
(14) | Consists of (i) 8,678,816 shares of common stock held by Insurance Company of the West and (ii) 500,000 shares of common stock purchased by Insurance Company of the West in the PIPE Financing. |
Shares of Common Stock |
Warrants (1) to Purchase Common Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered For Sale Hereby |
Number Beneficially Owner After Offering |
Percent Owner After Offering |
||||||||||||||||||||||||
75 & Sunny LP (2) |
165,000 | 165,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Alissa Fitzgerald (3) |
295,119 | 295,119 | — | — | — | — | — | |||||||||||||||||||||||||
Alpha Intelligence Capital Fund I (4) |
2,970,197 | 2,970,197 | — | — | — | — | — | — | ||||||||||||||||||||||||
Alumni Ventures - Rigetti Trust 2022 (5) |
100,000 | 100,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Alyeska Master Fund, LP (6) |
474,017 | 300,000 | 174,017 | * | — | — | — | — | ||||||||||||||||||||||||
Ancient 1604 LLC (7) |
136,250 | 136,250 | — | — | — | — | — | — | ||||||||||||||||||||||||
Asset Management Exchange CCF - AMX CCF Lansdowne Partners Developed Markets Long Only (8) |
105,988 | 105,988 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVG - BIV Rigetti Trust1 2020 (9) |
860,629 | 860,629 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVG - BIV Rigetti Trust2 2020 (10) |
1,022,123 | 1,022,123 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVG - BIV Rigetti Trust3 2020 (11) |
5,585,461 | 5,585,461 | — | — | — | — | — | — | ||||||||||||||||||||||||
AVGF-BIV 2 Rigetti 2017, LLC(12) |
29,429 | 29,429 | — | — | — | — | — | — | ||||||||||||||||||||||||
Bessemer Venture Partners X Institutional L.P. (13) |
10,450,110 | 10,450,110 | — | — | — | — | — | — | ||||||||||||||||||||||||
Bessemer Venture Partners X L.P. (14) |
11,132,108 | 11,132,108 | — | — | — | — | — | — | ||||||||||||||||||||||||
Brian Sereda (15) |
1,055,564 | 1,055,564 | — | — | — | — | — | — | ||||||||||||||||||||||||
Campbell Pension Plans Master Retirement Trust (16) |
11,587 | 11,587 | — | — | — | — | — | — | ||||||||||||||||||||||||
Canada Life Global Growth Equity Fund (T. Rowe Price) (17) |
10,052 | 10,052 | — | — | — | — | — | — | ||||||||||||||||||||||||
Cathy McCarthy (18) |
295,120 | 295,120 | — | — | — | — | — | — | ||||||||||||||||||||||||
Chad T. Rigetti (19) |
10,847,174 | 10,847,174 | — | — | — | — | — | — | ||||||||||||||||||||||||
Coronation Global Opportunities Fund (20) |
128,516 | 128,516 | — | — | — | — | — | — | ||||||||||||||||||||||||
Damien Hooper-Campbell (21) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Data Collective III, L.P. (22) |
1,673,615 | 1,673,615 | — | — | — | — | — | — | ||||||||||||||||||||||||
David Rivas (23) |
625,168 | 625,168 | — | — | — | — | — | — | ||||||||||||||||||||||||
DCVC Opportunity Fund II, L.P. (24) |
2,038,265 | 2,038,265 | — | — | — | — | — | — | ||||||||||||||||||||||||
DEE STREET GLOBAL EQUITY FUND (25) |
54,458 | 54,458 | — | — | — | — | — | — | ||||||||||||||||||||||||
Delaware Public Employees’ Retirement System (26) |
271,109 | 271,109 | — | — | — | — | — | — | ||||||||||||||||||||||||
Dr. Ray O. Johnson (27) |
317,908 | 317,908 | — | — | — | — | — | — | ||||||||||||||||||||||||
Equipsuper Pty Ltd as Trustee for Equipsuper Superannuation Fund (28) |
203,459 | 203,459 | — | — | — | — | — | — | ||||||||||||||||||||||||
Franklin Templeton Investment Funds - Franklin Technology Fund (29) |
1,500,000 | 1,500,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Gregg Renfrew (30) |
34,500 | 34,500 | — | — | — | — | — | — |
Shares of Common Stock |
Warrants (1) to Purchase Common Stock |
|||||||||||||||||||||||||||||||
Name |
Number Beneficially Owned Prior to Offering |
Number Registered for Sale Hereby |
Number Beneficially Owned After Offering |
Percent Owned After Offering |
Number Beneficially Owned Prior to Offering |
Number Registered For Sale Hereby |
Number Beneficially Owner After Offering |
Percent Owner After Offering |
||||||||||||||||||||||||
HKJC Investment Trust Fund - Equity Series Trust (31) |
125,169 | 125,169 | — | — | — | — | — | — | ||||||||||||||||||||||||
In-Q-Tel, (32) |
195,858 | 195,858 | — | — | — | — | — | — | ||||||||||||||||||||||||
Insurance Company of the West (33) |
9,178,816 | 9,178,816 | — | — | — | — | — | — | ||||||||||||||||||||||||
Jim Lanzone (34) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Katie Curnutte (35) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Kenneth Fox (36) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Keysight Technologies, Inc. (37) |
2,951,220 | 2,951,220 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne Developed Markets Long Only Master Fund Limited (38) |
770,276 | 770,276 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne DM Long Only Cayman Master L.P. (39) |
304,608 | 304,608 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne DMLO Davies Street LP (40) |
381,130 | 381,130 | — | — | — | — | — | — | ||||||||||||||||||||||||
Lansdowne ICAV - Lansdowne Developed Markets Long Only Fund (41) |
74,916 | 74,916 | — | — | — | — | — | — | ||||||||||||||||||||||||
Leslie Enterprises LP (42) |
1,004,110 | 1,004,110 | — | — | — | — | — | — | ||||||||||||||||||||||||
Mandy Birch (43) |
389,385 | 389,385 | — | — | — | — | — | — | ||||||||||||||||||||||||
Michael Clifton (44) |
62,500 | 62,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Michael Harburn (45) |
834,920 | 834,920 | — | — | — | — | — | — | ||||||||||||||||||||||||
Nimble Ventures, LLC (46) |
3,256,298 | 3,256,298 | — | — | — | — | — | — | ||||||||||||||||||||||||
Northgate CommsTech Innovations Partners, L.P. (47) |
4,266,442 | 4,266,442 | — | — | — | — | — | — | ||||||||||||||||||||||||
Palantir Technologies Inc. (48) |
1,000,000 | 1,000,000 | — | — | — | — | — | — | ||||||||||||||||||||||||
Peter Pace (49) |
295,120 | 295,120 | — | — | — | — | — | — | ||||||||||||||||||||||||
Public Service Pension Plan Fund (50) |
129,884 | 129,884 | — | — | — | — | — | — | ||||||||||||||||||||||||
Rajeev Singh (51) |
34,500 | 34,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Rick Danis (52) |
648,408 | 648,408 | — | — | — | — | — | — | ||||||||||||||||||||||||
Robert Gelfond (53) |
539,554 | 539,554 | — | — | — | — | — | — | ||||||||||||||||||||||||
Robert Reid (54) |
136,250 | 136,250 | — | — | — | — | — | — | ||||||||||||||||||||||||
Robert Rigetti (55) |
162,989 | 162,989 | — | — | — | — | — | — | ||||||||||||||||||||||||
Supernova Partners II LLC (56) |
12,868,000 | 12,868,000 | — | — | 4,450,000 | 4,450,000 | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Equity Fund (57) |
1,026,678 | 1,026,678 | — | — | — | — | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Growth Equity Pool (58) |
219,751 | 219,751 | — | — | — | — | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Growth Equity Trust (59) |
191,249 | 191,249 | — | — | — | — | — | — | ||||||||||||||||||||||||
T. Rowe Price Global Growth Stock Fund (60) |
358,875 | 358,875 | — | — | — | — | — | — | ||||||||||||||||||||||||
Taryn Naidu (61) |
1,747,915 | 1,747,915 | — | — | — | — | — | — | ||||||||||||||||||||||||
Teachers’ Pension Plan Fund (62) |
77,356 | 77,356 | — | — | — | — | — | — | ||||||||||||||||||||||||
Trinity Capital Inc. (63) |
833,132 | 833,132 | — | — | — | — | — | |||||||||||||||||||||||||
Trust U/W Carl M. Loeb FBO Arthur Loeb (64) |
12,500 | 12,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Trust U/W Carl M. Loeb FBO Elisabeth Levin (65) |
12,500 | 12,500 | — | — | — | — | — | — | ||||||||||||||||||||||||
Virginia Retirement System (66) |
244,749 | 244,749 | — | — | — | — | — | — | ||||||||||||||||||||||||
Witan Investment Trust PLC (67) |
249,214 | 249,214 | — | — | — | — | — | — |
* | Less than one percent. |
(1) | Represents the private placement warrants. |
(2) | Consists of shares of common stock issued in the PIPE Financing. The managing partner of 75 & Sunny LP is Spencer Racoff, who was a member of the Supernova Board prior to the Business Combination. |
(3) | Consists of 295,119 shares of common stock issuable upon exercise of options. Ms. Fitzgerald is a member of the Board. |
(4) | Consists of 200,000 shares of common stock issued in the PIPE Financing, 2,547,739 shares of common stock held of record and 222,458 shares issuable upon exercise of Rigetti assumed warrants. |
(5) | Consists of shares of common stock issued in the PIPE Financing. |
(6) | Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P. (“Master Fund”), has voting and investment control of the shares held by the Master Fund. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr. Parekh, however, disclaims any beneficial ownership of the shares held by the Master Fund. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, KY1-1104, Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago IL 60601. |
(7) | Consists of shares of common stock issued in the PIPE Financing. Alexander Klabin is the manager of Klabin Descendants Delaware Trust LLC, which is the sole member of Ancient 1604 LLC. Mr. Klabin was a member of the Supernova Board prior to the Business Combination. |
(8) | Consists of shares of common stock issued in the PIPE Financing. |
(9) | Consists of 2,772,613 shares of common stock held of record and 88,016 shares issuable upon exercise of Rigetti assumed warrants. |
(10) | Consists of 906,446 shares of common stock held of record and 115,677 shares issuable upon exercise of Rigetti assumed warrants. |
(11) | Consists of 5,344,241 shares of common stock held of record and 241,220 shares issuable upon exercise of Rigetti assumed warrants. |
(12) | Consists of 29,429 shares of common stock held of record. |
(13) | Consists of 9,481,710 shares of common stock held of record and 968,400 shares of common stock purchased in the PIPE Financing. Deer X & Co. L.P., or Deer X L.P., is the general partner of Bessemer Venture Partners X Institutional L.P., or Bessemer Institutional. Deer X & Co. Ltd., or Deer X Ltd., is the general partner of Deer X L.P. Adam Fisher, Robert P. Goodman, David Cowan, Jeremy Levine, Byron Deeter, Ethan Kurzweil, Alex Ferrara, Brian Feinstein and Stephen Kraus are the directors of Deer X Ltd. and hold the voting and dispositive power for Bessemer Institutional. Investment and voting decisions with respect to the securities held by Bessemer Institutional are made by the directors of Deer X Ltd. acting as an investment committee. Mr. Cowan disclaims beneficial ownership interest of the securities of the Company held by Bessemer Institutional except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in Bessemer Institutional. The address for Bessemer Institutional is c/o Bessemer Venture Partners, 1865 Palmer Avenue, Suite 104, Larchmont, NY 10538. |
(14) | Consists of 10,100,508 shares of common stock held of record and 1,031,600 shares of common stock purchased in the PIPE Financing. Deer X & Co. L.P., or Deer X L.P., is the general partner of Bessemer Venture Partners X L.P., or Bessemer X. Deer X & Co. Ltd., or Deer X Ltd., is the general partner of Deer X L.P. Adam Fisher, Robert P. Goodman, David Cowan, Jeremy Levine, Byron Deeter, Ethan Kurzweil, Alex Ferrara, Brian Feinstein and Stephen Kraus are the directors of Deer X Ltd. and hold the voting and dispositive power for Bessemer X. Investment and voting decisions with respect to the securities held by Bessemer X are made by the directors of Deer X Ltd. acting as an investment committee. Mr. Cowan disclaims beneficial ownership interest of the securities of the Company held by Bessemer X except to the extent of his pecuniary interest, if any, in such securities through an indirect interest in Bessemer X. The address for Bessemer X is c/o Bessemer Venture Partners, 1865 Palmer Avenue, Suite 104, Larchmont, NY 10538. |
(15) | Consists 1,055,564 shares issuable upon settlement of restricted stock units. Mr. Sereda serves as the Chief Financial Officer of Rigetti. |
(16) | Consists of shares of common stock issued in the PIPE Financing. |
(17) | Consists of shares of common stock issued in the PIPE Financing. |
(18) | Ms. McCarthy is a member of the Board. Consists of 295,120 shares issuable upon vesting and settlement of RSUs. |
(19) | Mr. Rigetti is the founder and Chief Executive Officer of Rigetti. Consists of 4,144,913 shares of common stock held of record, 3,219,251 shares issuable upon vesting and settlement of RSUs and 3,483,010 shares issuable upon exercise of warrants. |
(20) | Consists of shares of common stock issued in the PIPE Financing. |
(21) | The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(22) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 1,470,533 shares of common stock held of record and 153,062 shares issuable upon exercise of Rigetti assumed warrants. |
(23) | Consists of 241,814 shares of common stock issuable upon vesting and settlement of RSUs and 383,354 shares issuable upon exercise of options. Mr. Rivas is an executive officer of the Company. |
(24) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 1,807,640 shares of common stock held of record and 180,625 shares issuable upon exercise of Rigetti assumed warrants. |
(25) | Consists of shares of common stock issued in the PIPE Financing. |
(26) | Consists of shares of common stock issued in the PIPE Financing. |
(27) | Dr. Johnson is a member of the Board. Consists of 22,788 shares of common stock and 295,120 shares issuable upon exercise of options. |
(28) | Consists of shares of common stock issued in the PIPE Financing. |
(29) | Consists of shares of common stock issued in the PIPE Financing. |
(30) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(31) | Consists of shares of common stock issued in the PIPE Financing. |
(32) | Consists of 1,000 shares of common stock issued in the PIPE Financing, 177,458 shares of common stock held of record and 17,400 shares issuable upon exercise of Rigetti assumed warrants. |
(33) | Consists of 500,000 shares of common stock issued in the PIPE Financing and 8,678,816 shares of common stock held of record. |
(34) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(35) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(36) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(37) | Consists of shares of common stock issued in the PIPE Financing. |
(38) | Consists of shares of common stock issued in the PIPE Financing. |
(39) | Consists of shares of common stock issued in the PIPE Financing. |
(40) | Consists of shares of common stock issued in the PIPE Financing. |
(41) | Consists of shares of common stock issued in the PIPE Financing. |
(42) | Consists of 25,000 shares of common stock issued in the PIPE Financing and 979,110 shares of common stock held of record. |
(43) | Ms. Birch is a former employee of the Company. Consists of 147,341 shares of common stock held of record, 19,078 shares of common stock issuable upon vesting and settlement of restricted stock units and 222,966 shares of common stock issuable upon exercise of options. |
(44) | Mr. Clifton is a member of the Board. |
(45) | Mr. Harburn is an executive officer of the Company. Consists of 480,329 shares of common stock issuable upon vesting and settlement of RSUs and 354,591 shares of common stock issuable upon exercise of options. |
(46) | Consists of 3,145,069 shares of common stock held of record and 111,229 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(47) | Consists of 350,000 shares of common stock issued in the PIPE Financing and 3,471,526 shares of common stock held of record and 444,916 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(48) | Consists of shares of common stock issued in the PIPE Financing. |
(49) | The selling securityholder is a member of the Board. |
(50) | Consists of shares of common stock issued in the PIPE Financing. |
(51) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(52) | Consists of 260,932 shares of common stock issuable upon vesting and settlement of RSUs and 387,476 shares of common stock issuable upon exercise of options. Mr. Danis is an executive officer of the Company. |
(53) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 433,940 shares of common stock held of record and 55,614 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(54) | Consists of Founder Shares. The selling securityholder was a member of the Supernova Board prior to the Business Combination. |
(55) | Consists of 50,000 shares of common stock issued in the PIPE Financing, 101,867 shares of common stock held of record and 11,122 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(56) | Consists of 8,418,000 Founder Shares, 4,450,000 shares of common stock issuable upon exercise of the private placement warrants and 4,450,000 private placement warrants. Supernova Partners II LLC is governed by a board of managers consisting of four managers: Spencer M. Rascoff, Alexander M. Klabin, Robert D. Reid and Michael S. Clifton. As a result, each of Messrs. Rascoff, Klabin, Reid, and Clifton may be deemed to share beneficial ownership of |
the securities owned by Supernova Partners II LLC. However, each manager of Supernova Partners LLC has one vote, and the approval of a majority of the manager is required to approve any action of Supernova Partners LLC. Mr. Clifton is a member of the Board. Includes 2,479,000 Sponsor Vesting Shares that became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days, and (ii) 580,273 Sponsor Vesting Shares held by the Sponsor Holders became unvested and subject to forfeiture as of the Closing and will only vest if, during the five year period following the Closing, the volume weighted average price of common stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days. Any such shares held by the Sponsor Holders that remain unvested after the fifth anniversary of the Closing will be forfeited. The address for Supernova Sponsor is 4301 50th Street NW, Suite 300 PMB 1044, Washington, D.C. 20016. |
(57) | Consists of shares of common stock issued in the PIPE Financing. |
(58) | Consists of shares of common stock issued in the PIPE Financing. |
(59) | Consists of shares of common stock issued in the PIPE Financing. |
(60) | Consists of shares of common stock issued in the PIPE Financing. |
(61) | Consists of 199,075 shares of common stock held of record, 716,281 shares of common stock issuable upon exercise of options, 804,429 shares of common stock issuable upon settlement of restricted stock units, and 22,245 shares issuable upon exercise of Rigetti assumed warrants. Also includes 5,885 shares held by AlphaNuma LLC, of which Mr. Naidu is the sole member. Mr. Naidu serves as the Chief Operating Officer of Rigetti. |
(62) | Consists of shares of common stock issued in the PIPE Financing. |
(63) | Consists of 50,000 shares of common stock issued in the PIPE Financing and 783,132 shares of common stock issuable upon exercise of Rigetti assumed warrants. |
(64) | Consists of shares of common stock issued in the PIPE Financing. |
(65) | Consists of shares of common stock issued in the PIPE Financing. |
(66) | Consists of shares of common stock issued in the PIPE Financing. |
(67) | Consists of shares of common stock issued in the PIPE Financing. |
• | in whole and not in part; |
• | at a price of $0.01 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and |
• | if, and only if, the closing price of the shares of common stock equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “— Anti-dilution Adjustments |
• | in whole and not in part; |
• | at $0.10 per warrant; |
• | upon a minimum of 30 days’ prior written notice of redemption provided |
• | if, and only if, the closing price of shares of common stock equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a |
warrant as described under the heading “— Anti-dilution Adjustments |
Fair Market Value of Common Stock |
||||||||||||||||||||||||||||||||||||
Redemption Date (period to expiration of warrants) |
≤ | 10.00 |
11.00 |
12.00 |
13.00 |
14.00 |
15.00 |
16.00 |
17.00 |
≥ | 18.00 |
|||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
60 months |
0.261 | 0.281 | 0.297 | 0.311 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||||||||||||||||||||
57 months |
0.257 | 0.277 | 0.294 | 0.310 | 0.324 | 0.337 | 0.348 | 0.358 | 0.361 | |||||||||||||||||||||||||||
54 months |
0.252 | 0.272 | 0.291 | 0.307 | 0.322 | 0.335 | 0.347 | 0.357 | 0.361 | |||||||||||||||||||||||||||
51 months |
0.246 | 0.268 | 0.287 | 0.304 | 0.320 | 0.333 | 0.346 | 0.357 | 0.361 | |||||||||||||||||||||||||||
48 months |
0.241 | 0.263 | 0.283 | 0.301 | 0.317 | 0.332 | 0.344 | 0.356 | 0.361 | |||||||||||||||||||||||||||
45 months |
0.235 | 0.258 | 0.279 | 0.298 | 0.315 | 0.330 | 0.343 | 0.356 | 0.361 | |||||||||||||||||||||||||||
42 months |
0.228 | 0.252 | 0.274 | 0.294 | 0.312 | 0.328 | 0.342 | 0.355 | 0.361 | |||||||||||||||||||||||||||
39 months |
0.221 | 0.246 | 0.269 | 0.290 | 0.309 | 0.325 | 0.340 | 0.354 | 0.361 | |||||||||||||||||||||||||||
36 months |
0.213 | 0.239 | 0.263 | 0.285 | 0.305 | 0.323 | 0.339 | 0.353 | 0.361 | |||||||||||||||||||||||||||
33 months |
0.205 | 0.232 | 0.257 | 0.280 | 0.301 | 0.320 | 0.337 | 0.352 | 0.361 | |||||||||||||||||||||||||||
30 months |
0.196 | 0.224 | 0.250 | 0.274 | 0.297 | 0.316 | 0.335 | 0.351 | 0.361 | |||||||||||||||||||||||||||
27 months |
0.185 | 0.214 | 0.242 | 0.268 | 0.291 | 0.313 | 0.332 | 0.350 | 0.361 | |||||||||||||||||||||||||||
24 months |
0.173 | 0.204 | 0.233 | 0.260 | 0.285 | 0.308 | 0.329 | 0.348 | 0.361 | |||||||||||||||||||||||||||
21 months |
0.161 | 0.193 | 0.223 | 0.252 | 0.279 | 0.304 | 0.326 | 0.347 | 0.361 | |||||||||||||||||||||||||||
18 months |
0.146 | 0.179 | 0.211 | 0.242 | 0.271 | 0.298 | 0.322 | 0.345 | 0.361 | |||||||||||||||||||||||||||
15 months |
0.130 | 0.164 | 0.197 | 0.230 | 0.262 | 0.291 | 0.317 | 0.342 | 0.361 | |||||||||||||||||||||||||||
12 months |
0.111 | 0.146 | 0.181 | 0.216 | 0.250 | 0.282 | 0.312 | 0.339 | 0.361 | |||||||||||||||||||||||||||
9 months |
0.090 | 0.125 | 0.162 | 0.199 | 0.237 | 0.272 | 0.305 | 0.336 | 0.361 | |||||||||||||||||||||||||||
6 months |
0.065 | 0.099 | 0.137 | 0.178 | 0.219 | 0.259 | 0.296 | 0.331 | 0.361 | |||||||||||||||||||||||||||
3 months |
0.034 | 0.065 | 0.104 | 0.150 | 0.197 | 0.243 | 0.286 | 0.326 | 0.361 | |||||||||||||||||||||||||||
0 months |
— | — | 0.042 | 0.115 | 0.179 | 0.233 | 0.281 | 0.323 | 0.361 |
• | before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; |
• | upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (1) by persons who are directors and also officers and (2) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or |
• | on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. |
• | any merger or consolidation involving the corporation and the interested stockholder; |
• | any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; |
• | subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; |
• | any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or |
• | the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation. |
• | providing for a classified board of directors with staggered, three-year terms; |
• | the ability of the Board to issue up to 10,000,000 shares of preferred stock, including “blank check” preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; |
• | provide that the authorized number of directors may be changed only by resolution of the Board; |
• | provide that, subject to the rights of the holders of any series of preferred stock, any individual director or directors may be removed only with cause by the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single class; |
• | provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; |
• | require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission; |
• | provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice; |
• | provide that special meetings of our stockholders may be called by the chairperson of the Board, the chief executive officer or by the Board pursuant to a resolution adopted by a majority of the total number of authorized directors; and |
• | not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. |
• | 1% of the total number of our common stock then outstanding; or |
• | the average weekly reported trading volume of our common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
• | the issuer of the securities that was formerly a shell company has ceased to be a shell company; |
• | the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
• | the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and |
• | at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. |
• | an individual who is a citizen or resident of the United States; |
• | a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia; |
• | an estate, the income of which is subject to U.S. federal income tax regardless of its source; or |
• | a trust if (a) a U.S. court can exercise primary supervision over the trust’s administration and one or more U.S. persons have the authority to control all of the trust’s substantial decisions or (b) the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. |
• | the gain is effectively connected with the conduct of a trade or business by the non-U.S. Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the non-U.S. Holder); |
• | the non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or |
• | we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the non-U.S. Holder held our common stock or warrants and, in the case where shares of our common stock are regularly traded on an established securities market, (i) the non-U.S. Holder is disposing of our common stock and has owned, directly or constructively, more than 5% of our common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder’s holding period for the shares of our common stock or (ii) in the case where our warrants are regularly traded on an established securities market, the non-U.S. Holder is disposing of our warrants and has owned, directly or constructively, more than 5% of our warrants at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder’s holding period for the shares of our warrants. There can be no assurance that our common stock or warrants will be treated as regularly traded or not regularly traded on an established securities market for this purpose. |
• | purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; |
• | ordinary brokerage transactions and transactions in which the broker solicits purchasers; |
• | block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
• | an over-the-counter distribution in accordance with the rules of Nasdaq; |
• | through trading plans entered into by a selling securityholder pursuant to Rule 10b5-1 under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; |
• | short sales; |
• | distribution to employees, members, limited partners or stockholders of the selling securityholders; |
• | through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; |
• | by pledge to secured debts and other obligations; |
• | delayed delivery arrangements; |
• | to or through underwriters or broker-dealers; |
• | in “at the market” offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; |
• | in privately negotiated transactions; |
• | in options transactions; |
• | through a combination of any of the above methods of sale; or |
• | any other method permitted pursuant to applicable law. |
Page |
||||
RIGETTI COMPUTING, INC. |
||||
Unaudited Condensed Consolidated Financial Statements: |
||||
F-2 | ||||
F-3 | ||||
F-4 | ||||
F-5 | ||||
F-6 | ||||
F-7 | ||||
RIGETTI HOLDINGS, INC. |
||||
F-30 | ||||
Audited Consolidated Financial Statements: |
||||
F-31 | ||||
F-32 | ||||
F-33 | ||||
F-34 | ||||
F-35 | ||||
F-36 |
(In thousands) | March 31, |
December 31, |
||||||
2022 |
2021 |
|||||||
(Unaudited) |
||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash |
$ | $ | ||||||
Accounts receivable |
||||||||
Prepaid expenses and other current assets |
||||||||
Forward contract—assets |
||||||||
Deferred offering costs |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
Property and equipment, net |
||||||||
Restricted cash |
||||||||
Other assets |
||||||||
Goodwill |
||||||||
|
|
|
|
|||||
Total assets |
$ | $ | ||||||
|
|
|
|
|||||
Liabilities, redeemable convertible preferred stock and stockholders’ deficit |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses and other current liabilities |
||||||||
Convertible notes |
||||||||
Deferred revenue |
||||||||
Debt—current portion |
||||||||
Forward contract—liabilities |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
Debt—net of current portion |
||||||||
Derivative warrant liabilities |
||||||||
Earn-out liabilities |
||||||||
Other liabilities |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
Commitments and contingencies (Note 6) |
||||||||
Redeemable convertible preferred stock*, par value $ |
||||||||
Stockholders’ deficit: |
||||||||
Preferred Stock, par value $ |
||||||||
Common stock*, par value $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated other comprehensive gain |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity (deficit) |
( |
) | ||||||
|
|
|
|
|||||
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit |
$ | $ | ||||||
|
|
|
|
* | Shares of preferred stock and common stock have been retroactively restated to give effect to the Business Combination. |
Three Months Ended |
||||||||
March 31, |
||||||||
2022 |
2021 |
|||||||
(Unaudited) |
||||||||
Revenue |
$ | $ | ||||||
Cost of revenue |
||||||||
Total gross profit |
||||||||
Operating expenses: |
||||||||
Research and development |
||||||||
Sales and marketing |
||||||||
General and administrative |
||||||||
Total operating expenses |
||||||||
Loss from operations |
( |
) | ( |
) | ||||
Other (expense) income, net: |
||||||||
Interest expense |
( |
) | ( |
) | ||||
Change in fair value of derivative warrant liabilities |
||||||||
Change in fair value of earn-out liability |
||||||||
Transaction cost |
( |
) | ||||||
Other expense |
( |
) | ||||||
Total other income (expense), net |
( |
) | ||||||
Net loss before provision for income taxes |
( |
) | ( |
) | ||||
Provision for income taxes |
||||||||
Net loss |
$ | ( |
$ | ( |
||||
Net loss per share attribute to common stockholders—basic and diluted |
$ | ( |
$ | ( |
||||
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted* |
* | Weighted-average shares have been retroactively restated to give effect to the Business Combination. |
Three Months Ended |
||||||||
March 31, |
||||||||
2022 |
2021 |
|||||||
(Unaudited) |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Other comprehensive gain: |
||||||||
Foreign currency translation gain |
||||||||
Comprehensive loss |
$ | ( |
) | $ | ( |
) | ||
Redeemable Convertible Preferred Stock |
Common Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Gain |
Accumulated Deficit |
Total Stockholders’ (Deficit) Equity |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||||||||||||||||||
Balance, December 31, 2020 |
$ | $ | $ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||
Retroactive application of Business Combination (Note 3) |
( |
) | — | ( |
) | ( |
) | — | — | — | ||||||||||||||||||||||
Adjusted balance, beginning of period* |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options |
— | — | — | — | — | |||||||||||||||||||||||||||
Issuance of common stock upon exercise of common stock warrants |
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | — | ||||||||||||||||||||||||||
Foreign currency translation gain |
— | — | — | — | — | — | ||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
Balance, March 31, 2021 |
$ | $ | $ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||
Redeemable Convertible Preferred Stock |
Common Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Gain |
Accumulated Deficit |
Total Stockholders’ (Deficit) Equity |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||||||
(In thousands, except share and per share data) |
||||||||||||||||||||||||||||||||
Balance, December 31, 2021 |
$ | $ | $ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||
Retroactive application of Business Combination (Note 3) |
( |
) | — | ( |
) | ( |
) | — | — | — | ||||||||||||||||||||||
Adjusted balance, beginning of period* |
( |
) | ( |
) | ||||||||||||||||||||||||||||
Issuance of common stock upon conversion of legacy Series C and Series C-1 preferred stock in connection with the Business Combination (Note 3) |
( |
) | ( |
) | — | — | ||||||||||||||||||||||||||
Issuance of common stock upon exercise of legacy Rigetti stock options |
— | — | — | — | — | |||||||||||||||||||||||||||
Issuance of common stock upon exercise of legacy Rigetti common stock warrants |
— | — | — | — | — | |||||||||||||||||||||||||||
Issuance of common stock through Business Combination and PIPE financing, net of transaction costs and derivative liabilities (Note 3) |
— | — | — | — | ||||||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | — | — | ||||||||||||||||||||||||||
Foreign currency translation gain |
— | — | — | — | — | — | ||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||
Balance, March 31, 2022 |
$ | $ | $ | $ | $ | ( |
) | $ | ||||||||||||||||||||||||
* | Shares of legacy Redeemable Convertible Series C Preferred Stock, Redeemable Convertible Series C-1 Preferred Stock, legacy Class A common stock, and legacy Class B common stock have been retroactively restated to give effect to the Business Combination. |
Three Months Ended |
||||||||
March 31, |
||||||||
2022 |
2021 |
|||||||
(Unaudited) |
||||||||
Cash flows from operating activities |
||||||||
Net loss |
$ | ( |
$ | ( |
||||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
||||||||
Stock-based compensation |
||||||||
Change in fair value of earnout liability |
( |
) | — | |||||
Change in fair value of derivative warrant liabilities |
( |
) | — | |||||
Change in fair value of forward contract—liabilities |
( |
) | — | |||||
Amortization of debt issuance costs |
— | |||||||
Accretion of debt end of term liabilities |
— | |||||||
Amortization of exit fee asset |
— | |||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
||||||||
Prepaid expenses and other current assets |
( |
) | ||||||
Other assets |
( |
) | ( |
) | ||||
Deferred revenue |
( |
) | ( |
) | ||||
Accounts payable |
||||||||
Accrued expenses and other current liabilities |
||||||||
Other liabilities |
( |
) | ||||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
Cash flows from investing activities |
||||||||
Purchases of property and equipment |
( |
) | ( |
) | ||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
Cash flows from financing activities |
||||||||
Proceeds from Business Combination, net of transaction costs paid |
— | |||||||
Transaction costs paid directly by Rigetti |
( |
) | — | |||||
Proceeds from issuance of debt and warrants |
||||||||
Payments on debt issuance costs |
( |
) | — | |||||
Payment on loan and security agreement exit fees |
( |
) | — | |||||
Proceeds from issuance of common stock upon exercise of stock options and warrants |
||||||||
Net cash provided by financing activities |
||||||||
Effect of changes in exchange rate on cash and restricted cash |
||||||||
Net increase in cash and restricted cash |
||||||||
Cash and restricted cash at beginning of period |
||||||||
Cash and restricted cash at end of period |
$ | $ | ||||||
Supplemental disclosure of cash flow information: |
||||||||
Cash paid for interest |
$ | $ | ||||||
Supplemental disclosure of non-cash financing activity: |
||||||||
Fair value of loan and security agreement warrant liability |
$ | $ | — | |||||
Fair value of earn-out liability |
$ | $ | — | |||||
Fair value of private placement warrants liability |
$ | $ | — |
• | Former Legacy Rigetti stockholders have a controlling voting interest in the Company; |
• | The Company’s board of directors as of immediately after the closing is comprised of |
• | Legacy Rigetti management continues to hold executive management roles for the post-combination company and be responsible for the day-to-day operations. |
March 31, 2022 |
December 31, 2021 |
|||||||
(In thousands) |
||||||||
Cash |
$ | $ | ||||||
Restricted cash |
||||||||
Total cash and restricted cash |
$ | $ | ||||||
Valuation Assumptions |
Initial Recognition on March 2, 2022 |
March 31, 2022 |
||||||
Stock Price |
$ | $ | ||||||
Simulated trading days |
||||||||
Volatility (annual) |
% | % | ||||||
Risk-free rate |
% | % | ||||||
Estimated time to expiration (years) |
March 31, | ||||
Customer |
2022 |
2021 | ||
Customer A |
* | |||
Customer B |
||||
Customer C |
* | Customer accounted for less than 10% of revenue in the respective period |
March 31, |
December 31, |
|||||||
Customer |
2022 |
2021 |
||||||
Customer A |
% | * | ||||||
Customer B |
% | % | ||||||
Customer C |
% | * | ||||||
Customer D |
* | % | ||||||
Customer E |
* | % |
* | Customer accounted for less than 10% of accounts receivable in the respective period |
Amount (in thousands) |
||||
Cash - SNII trust and cash (net of redemption) |
$ | |||
Cash - PIPE |
||||
Cash - SNII operating account |
||||
Less: SNII transaction cost |
( |
) | ||
|
|
|||
Net Proceeds from Business Combination and PIPE |
$ |
|||
|
|
Common Stock - SNII Class A, outstanding prior to Business Combination |
||||
Less: redemption of SNII Class A ordinary shares |
( |
) | ||
Common Stock - SNII Class A ordinary shares |
||||
Common Stock - SNII Class B ordinary shares* |
||||
Shares issued in PIPE |
||||
Business Combination and PIPE shares |
||||
Common stock - Legacy Rigetti** |
||||
Common stock - exercise of Legacy Rigetti stock options immediately prior to the closing** |
||||
Common stock - exercise of Legacy Rigetti warrants immediately prior to the closing** |
||||
Common stock - upon conversion of Legacy Rigetti Series C preferred stock** |
||||
Common stock - upon conversion of Legacy Rigetti Series C-1 preferred stock** |
||||
|
|
|||
Total shares of common stock immediately after Business Combination |
||||
|
|
* | Includes (i) |
** | (i)all outstanding shares of Legacy Rigetti Common Stock as of immediately prior to the Closing (including Legacy Rigetti Common Stock resulting from the Legacy Rigetti Preferred Stock Conversion), were exchanged at an exchange ratio of C-1 Preferred Stock was |
Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Type of Goods or Service |
(In thousands) |
|||||||
Collaborative research and other professional services |
$ | $ | ||||||
Access to quantum computing systems |
||||||||
Quantum computing components |
$ | $ | ||||||
Timing of Revenue Recognition |
||||||||
Revenue recognized at a point in time |
$ | $ | ||||||
Revenue recognized over time |
||||||||
$ | $ | |||||||
March 31, 2022 |
December 31, 2021 |
|||||||
(In thousands) |
||||||||
Trade receivables |
$ | $ | ||||||
Unbilled receivables |
$ | $ | ||||||
Deferred revenue |
$ | ( |
) | $ | ( |
) |
March 31, 2022 |
||||
(In thousands) |
||||
Balance at beginning of period |
$ | ( |
) | |
Deferral of revenue |
( |
) | ||
Recognition of deferred revenue |
||||
Balance at end of period |
$ | ( |
) | |
Fair Value Hierarchy |
||||||||||||
Level 1 |
Level 2 |
Level 3 |
||||||||||
(in thousands) |
||||||||||||
Assets: |
||||||||||||
Forward Warrant Agreement |
$ | $ | $ | |||||||||
Total Assets |
$ | $ | $ | |||||||||
Liabilities: |
||||||||||||
Derivative warrant liability - Trinity Warrants |
$ | $ | $ | |||||||||
Derivative warrant liability-Private Placement Warrants |
||||||||||||
Derivative warrant liability-Public Warrants |
||||||||||||
Earn-out Liability |
||||||||||||
Total Liabilities |
$ | $ | $ | |||||||||
Derivative warrant liability - Trinity Warrants |
Derivative warrant liability-Private Placement Warrants |
Derivative warrant liability- Public Warrants |
Forward Warrant Agreement |
Earn-out Liability |
||||||||||||||||
Balance - December 31, 2021 |
$ | $ | $ | $ | $ | |||||||||||||||
Initial measurement on March 2, 2022 upon Business Combination (Note 3) |
||||||||||||||||||||
Change in fair values |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Balance - March 31, 2022 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
As of March 31, 2022 (in thousands) |
||||
Remainder of 2022 |
$ | |||
2023 |
||||
2024 |
||||
2025 |
||||
2026 |
||||
Total minimum future lease payments |
$ | |||
March 31, 2022 |
December 31, 2021 |
|||||||
(in thousands) |
||||||||
Outstanding principal amount |
$ | $ | ||||||
Add: accreted liability of final payment fee |
||||||||
Less: unamortized debt discount, long term |
( |
) | ( |
) | ||||
Less: current portion of long term debt - principal |
( |
) | ( |
) | ||||
Debt—net of current portion |
$ | $ | ||||||
Current portion of long term debt - principal |
$ | $ | ||||||
Less: current portion of unamortized debt discount |
( |
) | ( |
) | ||||
Debt—current portion |
$ | $ | ||||||
March 31, 2022 |
December 31, 2021 |
|||||||
(in thousands) |
||||||||
2022 |
$ | $ | ||||||
2023 |
||||||||
2024 |
||||||||
2025 |
||||||||
2026 |
||||||||
$ | $ | |||||||
Common Stock |
||||
Common Stock Warrants |
||||
Stock-Based Awards - Options Outstanding |
||||
Stock-Based Awards - RSUs Outstanding |
||||
Total |
||||
Valuation Assumptions |
Initial Recognition on March 2, 2022 |
March 31, 2022 |
||||||
Stock Price |
$ | $ | ||||||
Strike Price |
$ | $ | ||||||
Volatility (annual) |
% | % | ||||||
Risk-free rate |
% | % | ||||||
Estimated time to expiration (years) |
||||||||
Dividend yield |
% | % |
Warrant Class |
Shares |
Issuance Date |
Strike Price per Share |
Expiration Date |
||||||||||||
Common Stock Warrants |
$ |
Valuation Assumption - Common Stock Warrants |
March 31, 2022 |
|||
Stock price |
$ | |||
Strike price |
$ | |||
Volatility (annual) |
% | |||
Risk-free rate |
% | |||
Estimated time to expiration (years) |
||||
Dividend yield |
% |
March 31, 2022 |
December 31, 2021 |
|||||||
Vested Customer warrants |
||||||||
Unvested Customer warrants |
||||||||
Key Valuation Assumptions |
||||
Holding period (in years) |
||||
Risk free rate |
% | |||
Probability of occurring the contingency |
% | |||
Underlying value per share |
$ |
Number of Options |
Weighted-Average Exercise Price |
Average Remaining Contractual Term (In Years) |
Aggregate Intrinsic Value |
|||||||||||||
Outstanding - December 31, 2021 |
$ | $ | ||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | $ | $ | ||||||||||||
Forfeited and expired |
( |
) | $ | |||||||||||||
Outstanding - March 31, 2022 |
$ | $ | ||||||||||||||
Exercisable - March 31, 2022 |
$ | $ |
Number of RSUs |
Weighted-Average Exercise Price |
|||||||
Balance at December 31, 2021 |
||||||||
Granted |
$ | |||||||
Vested |
( |
|||||||
Forfeited |
( |
|||||||
Balance at March 31, 2022 |
||||||||
Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
(In thousands) |
||||||||
Research and development |
$ | $ | ||||||
Selling and marketing |
||||||||
General and administrative |
||||||||
$ | $ | |||||||
March 31, 2021 |
||||
Expected volatility |
% | |||
Weighted-average risk-free interest rate |
% | |||
Expected dividend yield |
% | |||
Expected term (in years) |
Three Months Ended March 31, |
||||||||
2022 |
2021 |
|||||||
Net Loss |
$ | ( |
) | $ | ( |
) | ||
Basic and diluted shares |
||||||||
Weighted-average Class A Common Stock outstanding |
||||||||
Loss per share for Class A Common Stock |
||||||||
— Basic |
$ | ( |
) | $ | ( |
) | ||
— Diluted |
$ | ( |
) | $ | ( |
) |
March 31, |
||||||||
2022 |
2021 |
|||||||
Convertible Series C-1 Preferred Stock (2) |
||||||||
Convertible Series C Preferred Stock (2) |
||||||||
Common Stock Warrants (2)(3) |
||||||||
Stock Options (2) |
||||||||
Restricted Stock Units(1) |
||||||||
(1) | The number of outstanding shares as of March 31, 2022 includes |
(2) | The number of outstanding shares as of March 31, 2021 have been retrospectively adjusted to reflect the Exchange Ratio. |
(3) | The number of outstanding shares as of March 31, 2022 and March 31, 2021 does not include |
Three Months Ended March 31, |
||||||||||||||||
2022 |
2021 |
|||||||||||||||
Amount (in thousands) |
% |
Amount (in thousands) |
% |
|||||||||||||
United States |
$ | % | $ | % | ||||||||||||
United Kingdom |
% | % | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
$ | % | $ | % | |||||||||||||
|
|
|
|
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash |
$ | 11,728,516 | $ | 22,202,388 | ||||
Accounts receivable |
1,542,540 | 479,374 | ||||||
Prepaid expenses and other current assets |
1,350,690 | 1,035,703 | ||||||
Deferred offering costs |
3,448,470 | — | ||||||
|
|
|
|
|||||
Total current assets |
18,070,216 | 23,717,465 | ||||||
Property and equipment, net |
22,497,484 | 20,140,872 | ||||||
Restricted cash |
317,134 | 317,134 | ||||||
Other assets |
164,341 | 129,363 | ||||||
Goodwill |
5,377,255 | 5,377,255 | ||||||
|
|
|
|
|||||
Total assets |
$ | 46,426,430 | $ | 49,682,089 | ||||
|
|
|
|
|||||
Liabilities, redeemable convertible preferred stock and stockholders’ deficit |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 1,970,998 | $ | 1,107,924 | ||||
Accrued expenses and other current liabilities |
4,035,615 | 1,603,299 | ||||||
Deferred revenue |
984,976 | 491,827 | ||||||
Debt - current portion |
1,290,538 | — | ||||||
|
|
|
|
|||||
Total current liabilities |
8,282,127 | 3,203,050 | ||||||
Debt - net of current portion |
23,500,494 | — | ||||||
Derivative warrant liabilities |
4,354,707 | — | ||||||
Other liabilities |
294,632 | 381,300 | ||||||
|
|
|
|
|||||
Total liabilities |
36,431,960 | 3,584,350 | ||||||
Commitments and contingencies (Note 6) |
||||||||
Redeemable convertible preferred stock*, par value $0.0001 per share. 80,974,757 shares authorized at December 31, 2021 and January 31, 2021; and 77,696,679 shares issued and outstanding at December 31, 2021 and January 31, 2021, respectively |
81,523,141 | 81,523,141 | ||||||
Stockholders’ deficit: |
||||||||
Common stock*, par value $0.000001 per share. 134,050,472 shares authorized at December 31, 2021 and January 31, 2021, respectively; 18,221,069 and 16,582,713 of shares issued and outstanding at December 31, 2021 and January 31, 2021, respectively |
23 | 21 | ||||||
Additional paid-in capital |
135,550,822 | 133,407,584 | ||||||
Accumulated other comprehensive gain |
51,815 | 56,825 | ||||||
Accumulated deficit |
(207,131,331 | ) | (168,889,832 | ) | ||||
|
|
|
|
|||||
Total stockholders’ deficit |
(71,528,671 | ) | (35,425,402 | ) | ||||
|
|
|
|
|||||
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit |
$ | 46,426,430 | $ | 49,682,089 | ||||
|
|
|
|
* | Shares of preferred stock and common stock have been retroactively restated to give effect to the Business Combination. |
11 Months Ended December 31, |
Year Ended January 31, |
|||||||
2021 |
2021 |
|||||||
Revenue |
$ | 8,196,306 | $ | 5,542,598 | ||||
Cost of revenue |
1,623,336 | 1,491,610 | ||||||
|
|
|
|
|||||
Total gross profit |
6,572,970 | 4,050,988 | ||||||
Operating expenses: |
||||||||
Research and development |
26,927,599 | 24,099,335 | ||||||
General and administrative |
11,299,068 | 13,157,735 | ||||||
Sales and marketing |
2,474,968 | 1,885,565 | ||||||
|
|
|
|
|||||
Total operating expenses |
40,701,635 | 39,142,635 | ||||||
|
|
|
|
|||||
Loss from operations |
(34,128,665 | ) | (35,091,647 | ) | ||||
|
|
|
|
|||||
Other (expense) income , net: |
||||||||
Gain on extinguishment of debt |
— | 8,913,532 | ||||||
Change in fair value of warrant liability |
(1,664,133 | ) | — | |||||
Interest expense |
(2,465,135 | ) | (51,666 | ) | ||||
Interest income |
9,852 | 60,154 | ||||||
Other income |
6,582 | 42,131 | ||||||
|
|
|
|
|||||
Total other (expense) income, net |
(4,112,834 | ) | 8,964,151 | |||||
Net loss before provision for income taxes |
(38,241,499 | ) | (26,127,496 | ) | ||||
|
|
|
|
|||||
Net loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
|
|
|
|
|||||
Net loss per share attribute to common stockholders - basic and diluted* |
$ | (2.23 | ) | $ | (1.61 | ) | ||
Weighted average shares used in computing net loss per share attributable to common stockholders – basic and diluted* |
17,146,853 | 16,230,951 |
* | Weighted-average shares and net loss per share have been retroactively restated to give effect to the Business Combination. |
11 Months Ended December 31, |
Year Ended January 31, |
|||||||
2021 |
2021 |
|||||||
Net loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
Other comprehensive loss: |
||||||||
Foreign currency translation (loss) gain |
(5,010 | ) | 72,136 | |||||
|
|
|
|
|||||
Comprehensive loss |
$ | (38,246,509 | ) | $ | (26,055,360 | ) | ||
|
|
|
|
Redeemable Convertible Preferred Stock |
Common Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Gain (Loss) |
Accumulated Deficit |
Total Stockholders’ Deficit |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||||||
Balance, January 31, 2020 |
14,154,064 | $ | 120,793,893 | 8,165,828 | $ | 8 | $ | 14,364,973 | $ | (15,311 | ) | $ | (142,762,336 | ) | $ | (128,412,666 | ) | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Retroactive application of Business Combination (Note 1) |
(3,014,971 | ) | — | (1,739,599 | ) | — | — | — | — | — | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Adjusted balance, beginning of period* |
11,139,093 | 120,793,893 | 6,426,229 | 8 | 14,364,973 | (15,311 | ) | (142,762,336 | ) | (128,412,666 | ) | |||||||||||||||||||||
Conversion of Series B/A preferred stock to common stock upon equity restructuring |
(11,139,093 | ) | (120,793,893 | ) | 2,784,748 | 4 | 120,793,889 | — | — | 120,793,893 | ||||||||||||||||||||||
Issuance of common stock upon modification of convertible notes |
— | — | 5,410,006 | 7 | 1,443,598 | — | — | 1,443,605 | ||||||||||||||||||||||||
Issuance of Series C preferred stock, net |
46,885,511 | 52,786,276 | — | — | — | — | — | — | ||||||||||||||||||||||||
Issuance of common stock warrants to investors |
— | — | — | — | 1,236,600 | — | — | 1,236,600 | ||||||||||||||||||||||||
Issuance of Series C-1 preferred stock to participating Series B/A preferred stock holders |
8,983,968 | 7,734,083 | — | — | (7,734,083 | ) | — | — | (7,734,083 | ) | ||||||||||||||||||||||
Issuance of Series C, C-1, common stock and warrants upon conversion of notes |
20,565,496 | 19,812,252 | 1,602,795 | 2 | 489,875 | — | — | 489,877 | ||||||||||||||||||||||||
Issuance of Series C and C-1 upon conversion of SAFE |
1,261,704 | 1,190,530 | — | — | — | — | — | — | ||||||||||||||||||||||||
Issuance of common stock warrants to customer |
— | — | — | — | 154,330 | — | — | 154,330 | ||||||||||||||||||||||||
Issuance of common stock upon exercise of common stock warrants |
— | — | 55,089 | — | 14,980 | — | — | 14,980 | ||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options |
— | — | 187,757 | — | 51,384 | — | — | 51,384 | ||||||||||||||||||||||||
Issuance of common stock upon release of acquisition escrow |
— | — | 115,901 | — | — | — | — | — | ||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | 2,592,038 | — | — | 2,592,038 | ||||||||||||||||||||||||
Foreign currency translation gain |
— | — | — | — | — | 72,136 | 72,136 | |||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | (26,127,496 | ) | (26,127,496 | ) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Balance, January 31, 2021 |
77,696,679 | $ | 81,523,141 | 16,582,525 | $ | 21 | $ | 133,407,584 | $ | 56,825 | $ | (168,889,832 | ) | $ | (35,425,402 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Issuance of common stock upon exercise of stock options |
1,404,966 | 2 | 374,900 | 374,901 | ||||||||||||||||||||||||||||
Issuance of common stock upon exercise of common stock warrants |
233,578 | — | 2,967 | 2,968 | ||||||||||||||||||||||||||||
Stock-based compensation |
— | — | — | — | 1,765,371 | — | — | 1,765,371 | ||||||||||||||||||||||||
Foreign currency translation loss |
— | — | — | — | — | (5,010 | ) | (5,010 | ) | |||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | (38,241,499 | ) | (38,241,499 | ) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Balance, December 31, 2021 |
77,696,679 | $ | 81,523,141 | 18,221,069 | $ | 23 | $ | 135,550,822 | $ | 51,815 | $ | (207,131,331 | ) | $ | (71,528,671 | ) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* | Shares of legacy Redeemable Convertible Series C Preferred Stock, Redeemable Convertible Series C-1 Preferred Stock, legacy Class A common stock, and legacy Class B common stock have been retroactively restated to give effect to the Business Combination. |
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Cash flows from operating activities |
||||||||
Net loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Depreciation and amortization |
4,651,129 | 4,299,263 | ||||||
Stock-based compensation |
1,765,371 | 2,592,038 | ||||||
Gain on extinguishment of debt |
— | (8,913,532 | ) | |||||
Change in fair value of derivative warrant liabilities |
1,664,133 | — | ||||||
Change in fair value of forward contract agreement liabilities |
230,000 | — | ||||||
Amortization of debt issuance costs |
512,755 | — | ||||||
Amortization of debt commitment fee asset |
94,405 | — | ||||||
Accretion of debt end of term liabilities |
121,585 | — | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(1,063,166 | ) | (290,399 | ) | ||||
Prepaid expenses and other current assets |
(314,988 | ) | 244,932 | |||||
Other assets |
(34,978 | ) | (2,248 | ) | ||||
Deferred revenue |
493,149 | (1,659,856 | ) | |||||
Accounts payable |
(388,574 | ) | (1,995,037 | ) | ||||
Accrued expenses and other current liabilities |
1,553,984 | 1,403,772 | ||||||
Other liabilities |
(86,666 | ) | 381,300 | |||||
|
|
|
|
|||||
Net cash used in operating activities |
(29,043,360 | ) | (30,067,263 | ) | ||||
|
|
|
|
|||||
Cash flows from investing activities |
||||||||
Purchases of property and equipment |
(7,007,742 | ) | (4,400,432 | ) | ||||
|
|
|
|
|||||
Net cash used in investing activities |
(7,007,742 | ) | (4,400,432 | ) | ||||
|
|
|
|
|||||
Cash flows from financing activities |
||||||||
Proceeds from issuance of convertible notes |
— | 2,200,000 | ||||||
Proceeds from issuance of debt and warrants |
27,000,000 | — | ||||||
Payments on debt issuance costs |
(247,140 | ) | — | |||||
Payments on deferred offering costs |
(1,548,489 | ) | — | |||||
Proceeds from issuance of preferred stock and warrants, net of issuance costs |
— | 54,022,876 | ||||||
Proceeds from issuance of common stock upon exercise of stock options |
374,901 | 51,384 | ||||||
Proceeds from issuance of common stock upon exercise of common stock warrants |
2,968 | 14,980 | ||||||
|
|
|
|
|||||
Net cash provided by financing activities |
25,582,240 | 56,289,240 | ||||||
|
|
|
|
|||||
Effect of changes in exchange rate on cash and restricted cash |
(5,010 | ) | 72,136 | |||||
Net (decrease) increase in cash and restricted cash |
(10,473,872 | ) | 21,893,681 | |||||
Cash and restricted cash at beginning of period |
22,519,522 | 625,841 | ||||||
|
|
|
|
|||||
Cash and restricted cash at end of period |
$ | 12,045,650 | $ | 22,519,522 | ||||
|
|
|
|
|||||
Supplemental disclosure of cash flow information: |
||||||||
Cash paid for interest |
$ | 1,488,890 | $ | 51,666 | ||||
Supplemental disclosure of non-cash financing activity: |
||||||||
Deferred offering costs in accounts payable and accrued expenses |
$ | 1,899,981 | $ | — | ||||
Fair value of loan and security agreement warrant liability |
$ | 2,690,574 | $ | — | ||||
Conversion of redeemable convertible preferred stock to common stock upon equity recapitalization |
$ | — | $ | 120,793,893 | ||||
Conversion of convertible notes to redeemable convertible preferred stock and warrants |
$ | — | $ | 19,874,439 | ||||
Issuance of redeemable convertible preferred stock upon equity recapitalization |
$ | — | $ | 7,734,083 | ||||
Issuance of common stock upon modification of convertible notes |
$ | — | $ | 1,443,605 | ||||
Conversion of SAFE to redeemable convertible preferred stock |
$ | — | $ | 1,190,530 | ||||
Conversion of convertible notes to common stock |
$ | — | $ | 427,690 | ||||
Issuance of common stock warrants to customer |
$ | — | $ | 154,330 |
1. |
ORGANIZATION AND BUSINESS |
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Cash |
$ | 11,728,516 | $ | 22,202,388 | ||||
Restricted cash |
317,134 | 317,134 | ||||||
|
|
|
|
|||||
Total cash and restricted cash |
$ | 12,045,650 | $ | 22,519,522 | ||||
|
|
|
|
• | Identify the contract with a customer |
• | Identify the performance obligations in the contract |
• | Determine the transaction price |
• | Allocate the transaction price to the performance obligations in the contract |
• | Recognize revenue when (or as) performance obligations are satisfied |
December 31, |
January 31, |
|||||||
Customer |
2021 |
2021 |
||||||
Customer A |
29 | % | * | |||||
Customer B |
20 | % | 32 | % | ||||
Customer C |
17 | % | 15 | % | ||||
Customer D |
16 | % | * | |||||
Customer E |
15 | % | 31 | % |
* | Customer accounted for less than 10% of revenue in the respective year |
11 Months Ended December 31, |
||||||||
2021 |
2020 |
|||||||
(Unaudited) | ||||||||
Revenue |
$ | 8,196,306 | $ | 5,105,824 | ||||
Cost of revenue |
1,623,336 | 1,344,916 | ||||||
|
|
|
|
|||||
Total gross profit |
6,572,970 | 3,760,908 | ||||||
Operating expenses: |
||||||||
Research and development |
26,927,599 | 22,843,637 | ||||||
General and administrative |
11,299,068 | 10,613,190 | ||||||
Sales and marketing |
2,474,968 | 1,947,447 | ||||||
|
|
|
|
|||||
Total operating expenses |
40,701,635 | 35,404,274 | ||||||
|
|
|
|
|||||
Loss from operations |
(34,128,665 | ) | (31,643,366 | ) | ||||
|
|
|
|
|||||
Other income (expense), net: |
||||||||
Gain on extinguishment of debt |
— | 8,913,532 | ||||||
Change in fair value of warrant liability |
(1,664,133 | ) | — | |||||
Interest expense |
(2,465,135 | ) | (51,666 | ) | ||||
Interest Income |
9,852 | 58,644 | ||||||
Other income |
6,582 | 71,737 | ||||||
|
|
|
|
|||||
Total other income (expense), net |
(4,112,834 | ) | 8,992,247 | |||||
Net loss before provision for income taxes |
||||||||
Provision for income taxes |
||||||||
|
|
|
|
|||||
Net loss |
$ |
(38,241,499 |
) |
$ |
(22,651,119 |
) | ||
|
|
|
|
|||||
Net loss per share attribute to common stockholders—basic and diluted |
$ | (2.23) | $ | (1.40) | ||||
Weighted average shares used in computing net loss per share attributable to common stockholders – basic and diluted* |
17,146,853 | 16,212,027 |
* | Weighted-average shares have been retroactively restated to give effect to the Business Combination. |
3. |
REVENUE RECOGNITION |
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Type of Goods or Service |
||||||||
Collaborative research and other professional services |
$ | 5,849,267 | $ | 2,919,507 | ||||
Access to quantum computing systems |
2,347,039 | 2,380,091 | ||||||
Quantum computing components |
— | 243,000 | ||||||
|
|
|
|
|||||
$ | 8,196,306 | $ | 5,542,598 | |||||
|
|
|
|
|||||
Timing of Revenue Recognition |
||||||||
Revenue recognized at a point in time |
$ | — | $ | 243,000 | ||||
Revenue recognized over time |
8,196,306 | 5,299,598 | ||||||
|
|
|
|
|||||
$ | 8,196,306 | $ | 5,542,598 | |||||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Trade receivables, net |
$ | 961,370 | $ | 327,301 | ||||
Unbilled receivables |
$ | 581,170 | $ | 152,073 | ||||
Deferred revenue - current |
$ | (984,976 | ) | $ | (491,827 | ) |
11 Months Ended |
Year Ended |
|||||||
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Balance at beginning of period |
$ | (491,827 | ) | $ | (2,151,683 | ) | ||
Deferral of revenue |
(904,502 | ) | (364,545 | ) | ||||
Recognition of deferred revenue |
411,353 | 2,024,401 | ||||||
|
|
|
|
|||||
Balance at end of period |
$ | (984,976 | ) | $ | (491,827 | ) | ||
|
|
|
|
4. |
FAIR VALUE MEASUREMENTS |
Fair Value Hierarchy |
||||||||||||
Level 1 |
Level 2 |
Level 3 |
||||||||||
At December 31, 2021 |
||||||||||||
Liabilities: |
||||||||||||
Derivative warrant liabilities |
$ | — | $ | — | $ | 4,354,707 | ||||||
Forward warrant agreement |
— | — | 230,000 | |||||||||
|
|
|
|
|
|
|||||||
Total Liabilities |
$ |
— |
$ |
— |
$ |
4,584,707 |
||||||
|
|
|
|
|
|
Convertible Notes |
Simple agreement for future equity |
Derivative Warrant Liabilities |
Forward Warrant Agreement |
|||||||||||||
Balance - January 31, 2020 |
$ | 26,892,459 | $ | 1,882,397 | $ | — | $ | — | ||||||||
Issuances |
— | — | — | — | ||||||||||||
Settlement |
(26,892,459 | ) | (1,882,397 | ) | — | — | ||||||||||
Loss on change in fair value |
— | — | — | — | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance - January 31, 2021 |
$ |
— |
$ |
— |
$ |
— |
$ |
— |
||||||||
|
|
|
|
|
|
|
|
|||||||||
Issuances |
$ | — | $ | — | $ | 2,690,574 | $ | 400,000 | ||||||||
Settlement |
— | — | — | — | ||||||||||||
Loss (gain) on change in fair value |
— | — | 1,664,133 | (170,000 | ) | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance - December 31, 2021 |
$ |
— |
$ |
— |
$ |
4,354,707 |
$ |
230,000 |
||||||||
|
|
|
|
|
|
|
|
5. |
SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Quantum computing fridges |
$ | 17,189,904 | $ | 14,251,579 | ||||
Process equipment |
16,169,598 | 12,747,756 | ||||||
Leasehold improvements |
4,296,620 | 4,077,646 | ||||||
IT Hardware |
2,427,681 | 1,999,082 | ||||||
Furniture and other assets |
1,246,068 | 1,246,067 | ||||||
|
|
|
|
|||||
Total property and equipment |
$ | 41,329,871 | $ | 34,322,130 | ||||
Less: Accumulated depreciation and amortization |
(18,832,387 | ) | (14,181,258 | ) | ||||
|
|
|
|
|||||
Property and equipment - net |
$ | 22,497,484 | $ | 20,140,872 | ||||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Interest - notes payable |
$ | 247,500 | $ | — | ||||
Other current liability - forward warrant agreement |
230,000 | — | ||||||
Payroll and other payroll costs |
962,399 | 739,893 | ||||||
Property and other taxes |
570,852 | 451,545 | ||||||
Subscription Fee |
555,832 | — | ||||||
Professional fees and other |
820,699 | 411,861 | ||||||
Deferred offering costs |
648,333 | — | ||||||
|
|
|
|
|||||
$ | 4,035,615 | $ | 1,603,299 | |||||
|
|
|
|
6. |
COMMITMENTS AND CONTINGENCIES |
Years Ending December 31, |
||||
2022 |
$ | 1,807,759 | ||
2023 |
901,316 | |||
2024 |
928,355 | |||
2025 |
956,206 | |||
2026 |
81,262 | |||
|
|
|||
Total minimum future lease payments |
$ | 4,674,898 | ||
|
|
7. |
FINANCING ARRANGEMENTS |
December 31, 2021 |
||||
Outstanding principal amount - stated value |
$ | 27,000,000 | ||
Add: Accrued final payment fee |
121,585 | |||
Less: Unamortized deferred financing costs |
(170,058 | ) | ||
Less: Unamortized debt discount |
(2,160,495 | ) | ||
|
|
|||
Total debt |
$ | 24,791,032 | ||
|
|
|||
Debt - current portion |
$ | 1,290,538 | ||
Debt - net of current portion |
23,500,494 | |||
|
|
|||
Total debt |
$ | 24,791,032 | ||
|
|
Total |
||||
2022 |
$ | 1,290,538 | ||
2023 |
8,750,354 | |||
2024 |
11,084,382 | |||
2025 |
5,874,726 | |||
|
|
|||
27,000,000 | ||||
|
|
8. |
REDEEMABLE CONVERTIBLE PREFERRED STOCK |
9. |
COMMON STOCK |
Class A Common Stock |
Class B Common Stock |
|||||||
Series C Preferred Stock |
54,478,261 | — | ||||||
Series C-1 Preferred Stock |
— | 2,902,287 | ||||||
Common Stock Warrants |
8,513,515 | — | ||||||
Stock-Based Awards - Options Outstanding |
11,468,275 | — | ||||||
Stock-Based Awards - RSUs Outstanding |
5,388,455 | — | ||||||
Stock-Based Awards - Options Available for Future Grant |
3,898,855 | — | ||||||
|
|
|
|
|||||
Total |
83,747,361 |
2,902,287 |
||||||
|
|
|
|
10. |
Warrants |
Warrant Class |
Shares |
Issuance Date |
Strike Price per Share |
Expiration Date |
||||||||||||
Common Stock Warrants |
783,129 | May 18, 2021 | $ | 0.270 | May 18, 2031 |
Valuation Assumption - Common Stock Warrants |
Initial Recognition |
December 31, 2021 |
||||||
Stock price |
$ | 3.65 | $ | 5.64 | ||||
Strike price |
$ | 0.27 | $ | 0.27 | ||||
Volatility (annual) |
51.90 | % | 105.10 | % | ||||
Risk-free rate |
1.65 | % | 1.51 | % | ||||
Estimated time to expiration (years) |
10 | 9 | ||||||
Dividend yield |
0.00 | % | 0.00 | % |
Valuation Assumption - |
Initial Recognition |
|||
Stock price |
$ | 0.27 | ||
Strike price |
$ | 0.01 | ||
Volatility (annual) |
51.50 | % | ||
Risk-free rate |
1.55 | % | ||
Estimated time to expiration (years) |
10 | |||
Dividend yield |
0.00 | % |
Valuation Assumption |
Initial Recognition |
|||
Stock price |
$ | 0.27 | ||
Strike price |
$ | 1.15 | ||
Volatility (annual) |
45.00 | % | ||
Risk-free rate |
1.29 | % | ||
Estimated time to expiration (years) |
10 | |||
Dividend yield |
0.00 | % |
December 31, 2021 |
January 31, 2021 |
|||||||
Vested Customer warrants |
1,072,237 | 804,176 | ||||||
Unvested Customer warrants |
1,608,359 | 1,876,420 | ||||||
|
|
|
|
|||||
2,680,596 | 2,680,596 | |||||||
|
|
|
|
11. |
FORWARD WARRANT AGREEMENT |
Key Valuation Assumptions |
||||
Holding period (in years) |
0.50 - 1.13 | |||
Risk free rate |
0.19% - 0.43 |
% | ||
Probability of occurring the contingency |
50% - 100 | % | ||
Underlying value per share |
$10.29 |
12. |
EQUITY PLANS |
Number of Options |
Weighted-Average Exercise Price |
Average Remaining Contractual Term (In Years) |
||||||||||
Outstanding - January 31, 2021 |
13,385,716 | $ | 0.34 | 9.0 | ||||||||
Granted |
49,187 | $ | 0.27 | |||||||||
Exercised |
(1,404,966 | ) | $ | 0.27 | ||||||||
Forfeited |
(561,662 | ) | $ | 0.27 | ||||||||
|
|
|
|
|
|
|||||||
Outstanding - December 31, 2021 |
11,468,275 | $ | 0.36 | 8.1 | ||||||||
|
|
|
|
|
|
|||||||
Exercisable - December 31, 2021 |
6,136,458 | $ | 0.39 | 7.9 |
11 Months Ended December 31, |
Year Ended January 31, |
|||||||
2021 |
2021 |
|||||||
Research and development |
$ | 975,136 | $ | 894,141 | ||||
Selling, general, and administrative expenses |
790,235 | 1,697,897 | ||||||
|
|
|
|
|||||
Total Stock-Based Compensation Expense |
$ | 1,765,371 | $ | 2,592,038 | ||||
|
|
|
|
December 31, |
January 31, | |||
2021 |
2021 | |||
Expected volatility |
46.8% | 41.2% - 43.1% | ||
Weighted-average risk-free interest rate |
1.07% | 0.3% - 0.6% | ||
Expected dividend yield |
0% | 0% | ||
Expected term (in years) |
6.1 years | 5.0 - 6.3 years | ||
Exercise price |
$0.27 | $0.27 |
13. |
NET LOSS PER SHARE |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Net Loss |
$ | (38,241,499 | ) | $ | (26,127,496 | ) | ||
Basic and diluted shares |
||||||||
Weighted-average Class A Common Stock outstanding |
17,146,853 | 16,230,951 | ||||||
Loss per share for Class A Common Stock |
||||||||
— Basic |
$ | (2.23 | ) | $ | (1.61 | ) | ||
— Diluted |
$ | (2.23 | ) | $ | (1.61 | ) |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Convertible Series C Preferred Stock |
54,478,261 | 5,478,261 | ||||||
Common Stock Warrants |
8,513,515 | 2,680,607 | ||||||
Stock Options |
11,468,275 | 13,385,716 | ||||||
Restricted Stock Units |
5,388,455 | — | ||||||
|
|
|
|
|||||
79,848,506 | 70,544,584 | |||||||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Convertible Series C-1 Preferred Stock |
23,218,418 | 23,218,418 | ||||||
|
|
|
|
|||||
23,218,418 | 23,218,418 | |||||||
|
|
|
|
14. |
INCOME TAXES |
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Domestic |
$ | (36,787,312 | ) | $ | (25,222,388 | ) | ||
Foreign |
(1,454,187 | ) | (905,108 | ) | ||||
|
|
|
|
|||||
$ | (38,241,499 | ) | $ | (26,127,496 | ) | |||
|
|
|
|
December 31, |
January 31, |
|||||||
2021 |
2021 |
|||||||
Deferred Tax Assets: |
||||||||
Net operating loss carryforwards |
$ | 46,552,853 | $ | 38,650,103 | ||||
Accruals and reserves |
146,603 | 96,320 | ||||||
Stock-based compensation |
744,300 | 278,581 | ||||||
Research and development credits |
10,986 | 10,986 | ||||||
Intangible assets |
32,324 | 35,516 | ||||||
|
|
|
|
|||||
Gross deferred assets |
47,487,066 | 39,071,506 | ||||||
Valuation allowance |
(46,066,606 | ) | (38,051,098 | ) | ||||
|
|
|
|
|||||
Net Deferred Tax Assets |
1,420,460 | 1,020,408 | ||||||
Deferred Tax Liabilities: |
||||||||
Property and equipment |
$ | (1,420,460 | ) | $ | (1,020,408 | ) | ||
|
|
|
|
|||||
Total Deferred Tax Liabilities |
(1,420,460 | ) | (1,020,408 | ) | ||||
|
|
|
|
|||||
Total Net Deferred Tax Assets |
$ | — | $ | — | ||||
|
|
|
|
11 Months Ended December 31, 2021 |
Year Ended January 31, 2021 |
|||||||
Component |
Rate Impact |
Rate Impact |
||||||
Total pre-tax book income |
21 | % | 22 | % | ||||
State and local income taxes |
0 | % | 0 | % | ||||
Permanent differences |
-1 | % | -2 | % | ||||
Rate differential |
0 | % | 0 | % | ||||
Return to provision true up |
1 | % | -11 | % | ||||
Change in valuation allowance |
-21 | % | -9 | % | ||||
|
|
|
|
|||||
Total: |
0 | % | 0 | % | ||||
|
|
|
|
Beginning balance at February 1, 2021 |
$ | 4,672,209 | ||
Current year increase(decrease) |
— | |||
Prior year adjustment - increase(decrease) |
— | |||
|
|
|||
Ending balance at December 31, 2021 |
$ | 4,672,209 | ||
|
|
15. |
SEGMENTS |
11 Months Ended December 31, |
Year Ended January 31, |
|||||||
2021 |
2021 |
|||||||
United States |
$ | 5,826,004 | $ | 5,108,847 | ||||
United Kingdom |
2,370,302 | 412,747 | ||||||
Australia |
— | 21,004 | ||||||
|
|
|
|
|||||
$ | 8,196,306 | $ | 5,542,598 | |||||
|
|
|
|
16. |
SUBSEQUENT EVENTS |
• | On March 1, 2022, pursuant to the Merger Agreement, Supernova filed a notice of deregistration with the Cayman Islands Registrar of Companies, together with the necessary accompanying documents, and filed a certificate of incorporation and a certificate of corporate domestication with the Secretary of State of the State of Delaware, under which Supernova was domesticated and continues as a Delaware corporation, changing its name to “Rigetti Computing, Inc.” |
• | As a result of and upon the effective time of the Domestication, among other things, (1) each then issued and outstanding Supernova Class A ordinary share converted automatically, on a one-for-one one-for-one one-fourth of one New Rigetti Warrant. No fractional shares were issued upon exercise of the New Rigetti. |
• | On the Closing Date, pursuant to the Merger Agreement, New Rigetti consummated the merger transaction contemplated by the Merger Agreement, following approval at the Extraordinary General Meeting on February 28, 2022, whereby (i) the First Merger occurred and (ii) immediately following the consummation of the First Merger, the Second Merger occurred. |
• | Immediately prior to the effective time of the First Merger, all shares of Legacy Rigetti Preferred Stock converted into shares of Legacy Rigetti Common Stock in accordance with the Amended and Restated Certificate of Incorporation of Legacy Rigetti (the “Legacy Rigetti Preferred Stock Conversion”). |
• | Each share of Legacy Rigetti Common Stock (including Legacy Rigetti Common Stock resulting from the Legacy Rigetti Preferred Stock Conversion) that was issued and outstanding immediately prior to the First Merger was cancelled and converted into 78,959,579 shares of New Rigetti Common Stock. |
• | Each warrant to purchase Legacy Rigetti Common Stock converted into a warrant to purchase shares of New Rigetti Common Stock subject to the same terms and conditions as were applicable to the original Legacy Rigetti warrants, and with an exercise price and number of shares of New Rigetti Common Stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | Each option to purchase Legacy Rigetti Common Stock converted into an option to purchase shares of New Rigetti Common Stock subject to the same terms and conditions as were applicable to the original Legacy Rigetti options, and with an exercise price and number of shares of New Rigetti Common Stock purchasable based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | Each restricted share of Legacy Rigetti Common Stock was exchanged for restricted shares of New Rigetti Common Stock subject to the same terms and conditions as were applicable to the original Legacy restricted shares, and with the number of shares of New Rigetti Common Stock based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | Each Legacy Rigetti restricted stock unit award converted into a restricted stock unit award to receive shares of New Rigetti Common Stock subject to the same terms and conditions as were applicable to the original Legacy restricted stock unit awards, and with the number of shares of New Rigetti Common Stock to which the restricted stock unit award relates based on the Exchange Ratio and other terms contained in the Merger Agreement. |
• | The issuance and sale of (i) 10,251,000 shares of New Rigetti Common Stock for a purchase price of $10.00 per share and (ii) 4,390,244 shares of New Rigetti Common Stock for a purchase price of $10.25 per share, generated aggregate gross proceeds of $147.5 million in PIPE Financing pursuant to the Subscription Agreements. |
• | Pursuant to the Sponsor Support Agreement, at the Closing (i) 2,479,000 shares of New Rigetti Common Stock held by the Sponsor (the “Promote Sponsor Vesting Shares”) became subject to vesting and are considered unvested and will only vest if, during the five year period following the Closing, the volume weighted average price of New Rigetti Common Stock equals or exceeds $12.50 for any twenty trading days within a period of thirty consecutive trading days, and (ii) 580,997 shares of New Rigetti Common Stock held by the Sponsor (“Sponsor Redemption-Based Vesting Shares”) became subject to vesting and considered unvested and will only vest if, during the five year period following the Closing, the volume weighted average price of New Rigetti Common Stock equals or exceeds $15.00 for any twenty trading days within a period of thirty consecutive trading days (collectively, the Promote Sponsor Vesting Shares and Sponsor Redemption-Based Vesting Shares, “Sponsor Earn Out Shares”). Any Sponsor Earn Out Shares that remain unvested after the fifth anniversary of the Closing will be forfeited. |
• | In connection with the execution of the Merger Agreement, Legacy Rigetti entered into a warrant subscription agreement with a strategic partner, Ampere, for the purchase of a warrant for an aggregate purchase price (including amounts from exercise) of $10,000,000. At the Closing, the warrant agreement was assumed by New Rigetti as a result of the Mergers. The warrant provides for the purchase of an aggregate of 1,000,000 shares of New Rigetti Common Stock at an exercise price of $0.0001. Ampere is required to pay $5.0 million no later than (i) the Closing or |
(ii) June 30, 2022, and upon such payment the warrant will vest and be exercisable by Ampere with respect to 500,000 shares of New Rigetti Common Stock pursuant to the terms of the warrant. No such purchase or payment has been made as of the Closing Date regarding this first $5.0 million. Ampere is required to pay an additional $5.0 million no later than the second anniversary of the date of the warrant subscription agreement, and upon such payment, the warrant will vest and be exercisable by Ampere with respect to the remaining 500,000 shares of New Rigetti Common Stock pursuant to the terms of the warrant. |
Item 13. |
Other Expenses of Issuance and Distribution. |
Amount |
||||
SEC registration fee |
$ | 72,881 | ||
Accountants’ fees and expenses |
100,000 | |||
Legal fees and expenses |
200,000 | |||
Printing fees |
50,000 | |||
Miscellaneous |
2,119 | |||
|
|
|||
Total expenses |
$ | 425,000 | ||
|
|
Item 14. |
Indemnification of Directors and Officers. |
• | for any transaction from which the director derives an improper personal benefit; |
• | for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
• | for any unlawful payment of dividends or redemption of shares; or |
• | for any breach of a director’s duty of loyalty to the corporation or its stockholders. |
Item 15. |
Recent Sales of Unregistered Securities . |
Item 16. |
Exhibits and Financial Statement Schedules . |
Incorporated by Reference |
||||||||||||||||||
Exhibit No. |
Description |
Schedule/ Form |
File No. |
Exhibit |
Filing Date |
|||||||||||||
10.28# |
Amended & Restated Employment Agreement, dated February 2, 2022, between Rigetti Holdings, Inc. and Mike Harburn. | S-4/A |
333-260692 |
10.28 | February 8, 2022 | |||||||||||||
10.29# |
Amended & Restated Employment Agreement, dated February 2, 2022, between Rigetti Holdings, Inc. and Rick Danis. | S-4/A |
333-260692 |
10.29 | February 8, 2022 | |||||||||||||
10.30# |
Executive Employment Agreement, dated March 14, 2022, between Rigetti Computing, Inc. and Greg Peters. | S-1 | 333-263798 | 10.30 | March 23, 2022 | |||||||||||||
16.1 |
Letter from Marcum LLP to the SEC. | 8-K |
001-40140 |
16.1 | March 7, 2022 | |||||||||||||
21.1 |
List of Subsidiaries of Rigetti Computing, Inc. | 8-K |
001-40140 |
21.1 | March 7, 2022 | |||||||||||||
23.1* |
Consent of BDO USA LLP | |||||||||||||||||
23.2 |
Consent of Cooley LLP (included in Exhibit 5.1) | S-1 | 333-263798 | 5.1 | March 23, 2022 | |||||||||||||
24.1 |
Power of Attorney | S-1 | 333-263798 | 24.1 | March 23, 2022 | |||||||||||||
101.INS* |
Inline XBRL Instance Document | |||||||||||||||||
101.SCH* |
Inline XBRL Taxonomy Extension Schema Document | |
||||||||||||||||
101.CAL* |
Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
||||||||||||||||
101.DEF* |
Inline XBRL Taxonomy Extension Definition Linkbase Document | |
||||||||||||||||
101.LAB* |
Inline XBRL Taxonomy Extension Label Linkbase Document | |
||||||||||||||||
101.PRE* |
Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
||||||||||||||||
104* |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||||||||||||
107** |
Filing Fee Table |
* | Filed herewith. |
** | Previously filed. |
+ | The schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. |
# | Indicates management contract or compensatory plan or arrangement. |
Item 17. |
Undertakings . |
(a) | The undersigned registrant hereby undertakes as follows: |
(1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
(i) | To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; |
(ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; |
(iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |
(2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
(3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(4) | That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: |
(i) | Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and |
(ii) | Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration |
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. |
(5) | That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
(i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
(ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; |
(iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or our securities provided by or on behalf of the undersigned registrant; and |
(iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
(b) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the undersigned pursuant to the foregoing provisions, or otherwise, the undersigned has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the undersigned of expenses incurred or paid by a director, officer or controlling person of the undersigned in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the undersigned will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
RIGETTI COMPUTING, INC. | ||
By: | /s/ Chad Rigetti | |
Chad Rigetti | ||
Chief Executive Officer |
Signature |
Title |
Date | ||
/s/ Chad Rigetti |
Chief Executive Officer and Director | May 24, 2022 | ||
Chad Rigetti | (Principal Executive Officer) | | ||
/s/ Brian Sereda |
Chief Financial Officer | May 24, 2022 | ||
Brian Sereda | (Principal Financial Officer and Principal Accounting Officer) | | ||
* |
Director | May 24 2022 | ||
Michael Clifton | ||||
* |
Director | May 24, 2022 | ||
David Cowan | |
| ||
* |
Director | May 24, 2022 | ||
Alissa Fitzgerald | |
| ||
* |
Director | May 24, 2022 | ||
Ray Johnson | |
| ||
* |
Director | May 24, 2022 | ||
Cathy McCarthy | |
| ||
* |
Chairman of the Board of Directors | May 24, 2022 | ||
Gen. Peter Pace | |
| ||
* |
Director | May 24, 2022 | ||
H. Gail Sandford | |
|
* By: /s/ Chad Rigetti Chad Rigetti Attorney-in-Fact |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Rigetti Computing, Inc.
Berkeley, California
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 7, 2022, except for the effects of the recapitalization described in Note 1, as to which the date is May 24, 2022, relating to the consolidated financial statements of Rigetti Holdings, Inc., which is contained in that Prospectus.
We also consent to the reference to us under the caption Experts in the Prospectus.
/s/ BDO USA, LLP
Spokane, Washington
May 24, 2022